The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

12-2015

MOLECULAR REGULATION OF VASCULAR CALCIFICATION IN
MURINE MODELS OF ATHEROSCLEROSIS
Shanshan Gao

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Biotechnology Commons, Cell Biology Commons, Medicine and Health Sciences
Commons, and the Molecular Biology Commons

Recommended Citation
Gao, Shanshan, "MOLECULAR REGULATION OF VASCULAR CALCIFICATION IN MURINE MODELS OF
ATHEROSCLEROSIS" (2015). The University of Texas MD Anderson Cancer Center UTHealth Graduate
School of Biomedical Sciences Dissertations and Theses (Open Access). 640.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/640

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

MOLECULAR REGULATION OF VASCULAR CALCIFICATION IN MURINE
MODELS OF ATHEROSCLEROSIS
by
Shanshan Gao,B.S.

APPROVED:
______________________________
Yong-jian Geng,M.D., Ph.D.
Advisory Professor
______________________________
Jianping Jin , Ph.D.
______________________________
Melvin E Klegerman, Ph.D.
______________________________
Ba-bie Teng, Ph.D.
______________________________
Chu-Huang "Mendel" Chen, M.D.,Ph.D.
______________________________
Mikael J,Akesson-Wassler, Ph.D.

APPROVED:

____________________________
Dean, The University of Texas
Graduate School of Biomedical Sciences at Houston

MOLECULAR REGULATION OF VASCULAR CALCIFICATION IN MURINE
MODELS OF ATHEROSCLEROSIS

A
DISSERTATION
Presented to the Faculty of
The University of Texas
Health Science Center at Houston
and
The University of Texas
MD Anderson Cancer Center
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
DOCTOR OF PHILOSOPHY

by
Shanshan Gao, Bachelor of Science
Houston, Texas
December, 2015

Acknowledgements
I would like to thank people who have helped me within the past 5 years.
I feel fortunate to work in Dr Geng’s lab and have him as my supervisor. Dr
Geng encouraged me to study things I am interested in and provided me precious
academic instructions as well as guidance scientific presentation skills and
writing skills. I would also like to thank my other committee members including
Dr Jianping Jin, Dr Ba-bie Teng, Dr Melvin E Klegerman and Dr Chu-huang
Chen, who gave me professional suggestions in my every single committee
meeting.
Dr Geng has a wonderful research group with hard-working and smart
people. I want to thank Dr Michael Wassler, our senior research scientist, who
tought me all the biotechniques and worked with me for troubleshooting when I
joined this lab at the very beginning. He is from Sweden but with a hot and
passionate heart for science. Harnath, our dear lab manager and a handy man,
showed me how to perform animal experiments and was always the source of my
happiness when he chatted with me in the lab. Dr Song Gao, our postdoc fellow,
took me to different seminars which broadened my horizon. Dr Yangxin Li, our
previous assistant professor, is a knowledgeable, optimistic scientist, who has
lots of novel ideas.
I made new friends in Houston, who care for me and support me when I
was upset or stressful. Suet-Nee Chen from Dr AJ Marian’s lab and Yang Xiao
from Dr James Martin’s lab generously let me use their ch1emicals and reagents,

1

which enabled me to continue my experiments even when our reagents were out
of stock.
And last but not least, I want to express my gratitude to my dear parents,
without whom I won’t be able to stand here and complete what I have been doing.
My mom has never forced me to do anything I don’t like since I was small, and
she acts like one of my friends, giving me strength and courage through her
words. My dad is the person who initiated my curiosity in biology. He taught me
how to be true to myself and stay patient and calm no matter what happens,
which I appreciate deeply.
As a beginner in science, I am lucky enough to have love and support from so
many people, and I will try my best to establish myself in this field in the future. I
strongly believe the completion of my PhD degree is not the finishing line yet a new
starting point.

2

Molecular Regulation on Vascular Calcification in Murine Models of
Atherosclerosis

Shanshan Gao,B.S.
Advisory Advisor: Yong-jian Geng, M.D.,Ph.D.
Background: Calcification occurs often in the atherosclerotic lesions of
patients with coronary heart disease and animals with hypercholesterolemia, such as
apolipoprotein-E deficient (ApoE-/-) mice. However, the mechanism(s) underlying the
development of calcification in atherosclerosis remains unclear. ApoE acts as a lipid
transporter, but also has been recognized as a potential regulator of osteogenesis.
Little information is available as to whether ApoE has any direct impact on
osteogenesis and calcification in vascular smooth muscle cells (VSMC). Several
signal transduction pathways play a role in regulation of calcification, including the
Wnt/β-catenin system and potentially GTAP, an ubiquitin-conjugating enzyme
responsible for protein degradation, which participates in the homeostasis of proteins
and metabolites in stem cells. The long-term goal of this study is to delineate the
molecular pathway(s) by which ApoE regulates expression of osteogenic genes and
calcification in vascular VSMC of atherosclerotic lesions.
Hypothesis: ApoE functions as an inhibitor of vascular calcification, through
regulation of the function of Wnt/β-catenin and GTAP signaling pathways.
3

Methods and Results: ApoE-/- and wild type control mice were used for
histopathology and cell culture studies. Compared to the aortic tissue and VSMCs of
wild type C57BL/6J mice, ApoE-/- aortic tissue and VSMCs from ApoE-/- mice
showed markedly increased calcification, and enhanced expression of pro-osteogenic
genes but lowered expressions of myogenic biomarkers. Incubation of VSMCs with
native ApoE protein added to culture or ApoE cDNA delivery by plasmid transfection
or lentiviral infection reduced the levels of osteogenic genes (e.g. Runx2, BMP-2 and
ALP) as well as calcification in ApoE-/- VSMCs exposed to elevated inorganic
phosphate (Pi). The genetically modified VSMCs isolated from ApoE-/- mice
displayed inceased activation of the canonical Wnt/β-catenin pathway at the presence
of Pi, which could be reversed by incubation with native ApoE protein in culture. The
GTAP-deficient aortic rings developed more severe calcification when exposed to Pi.
Moreover, the half-life of the osteogenesis-regulator Runx2 shortened in VSMCs with
GTAP overexpression.
Conclusion: ApoE serves as a critical inhibitor of vascular calcification
through the Wnt/β-catenin pathway. This study provides direct evidence that ApoE
regulates calcification by regulating expression of certain pro-osteogenic factors, such
as Runx2, BMP2 and ALP. Besides, GTAP is identified as a novel regulator of
osteogenesis by mediating Runx2 protein stability.
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Chapter 1： Background

1. Atherosclerosis and Vascular Calcification
1.1 Vascular calcification in the arterial tissues and atherosclerosis
Calcification is a common histopathological condition seen in aging or
diseased organs and tissues, particularly arteries with atherosclerosis and other
disorders which can cause vascular tissue injury. It frequently occurs in the arterial
tissues of people over 55-65 years old, and may represent a hallmark of certain types
of atherosclerotic lesions, especially those with active vascular cell proliferation and
inflammation[1].In the early phase of atherosclerosis, the lesions are largely restricted
to the intima and the media of the arteries [2, 3]. During vascular calcification,
calcium mineral deposition accumulates in and eventually stiffens arteries, causing
substantial morbidity, including hypertension, myocardial ischemia and congestive
heart failure[4].
The development of vascular calcification resembles osteogenesis, in which
non-calcifying cells are induced to express osteogenic genes, and attract calcium to
form insoluble deposits. Normally, contractile vascular smooth muscle cells (VSMCs)
express low or no osteogenic genes but under the stimulation of atherogenic factors,
VSMCs transdifferentiate into osteoblast-like cells and undergo calcification[5].
Calcium deposition can be found in atherosclerotic plaques, and atherosclerotic
calcification is usually accompanied by chronic inflammation [6]. Of note, vascular
calcification in later stages is still considered irreversible nowadays due to the
14

insolubility of calcium deposits and, therefore, prevention and regulation of
calcification in earlier stages are of great importance.
Atherosclerosis is characterized by plaque build-up inside tissues inside the
arterial walls, which can narrow the lumen of the blood vessels and cause thrombosis
if rupture happens. Large quantities of epidemiological investigations have revealed
risk factors linked to atherosclerosis such as hyperlipidemia, diabetes mellitus,
smoking, hypertension and aging [7]. Atherosclerotic plaque contains cholesterol,
fatty substances and cellular waste products[8, 9]; rupture of plaques releases
pro-thrombogenic and pro-coagulating tissue factors, which trigger formation of
thrombi, subsequently disruption of the blood stream, and consequently ischemia of
distal organs or tissues, namely the heart and brain[10]. Calcium deposits are
frequently found in atherosclerotic lesions as well [11]. Calcification can start early
and accelerate as atherosclerosis progresses.

1.2 The role of Apolipoprotein-E in vascular calcification

Apolipoprotein E (ApoE), 299 amino acids long, is a 34kDa protein that
consists of two major domains: the lipid-binding domain and the receptor-binding
domain. Multiple functions of ApoE have been identified, such as regulation of
glucose metabolism [12], beta-amyloid aggregation (Aß) and tangle formation [13,
14], but the best-known feature of ApoE is its capability of binding-lipid
capability[15]. Characterized as a secreted protein, ApoE is mainly synthesized in the
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liver and brain, but is also widely distributed in other organs. ApoE facilitates the
transport and thus clearance of lipid in brain and the circulation system. There are
three isoforms of ApoE: ApoE2 (Cys112, Cys158), ApoE3 (Cys112, Arg158), and
ApoE4 (Arg112, Arg158), which differ in amino acid(s) at positions 112 or/and 158.
The variance of amino acids at these positions alters the structure and functions of
ApoE[16, 17]. ApoE2 exhibits a lower-affinity binding to receptors in comparison to
ApoE3 and ApoE4[18]. ApoE2 and ApoE3 preferentially bind to HDL while ApoE4
prefers VLDL [19].ApoE2 is associated with risks of atherosclerosis [20], whereas
ApoE4 has been implicated in Alzheimer’s disease [21], impaired cognitive function
[22], HIV[23] and atherosclerosis[15]. Lack of ApoE leads to abnormally elevated
level of lipids called hyperlipidemia.

Apolipoprotein-E knockout (ApoE-/-) mice

spontaneously develop atherosclerosis in an age-dependent manner [24].C57BL/6
mice at a young age (5-8 weeks old) can be induced to develop vascular calcification
with vitamin D injection in the absence of atherosclerosis [25].
ApoE-/- mice tend to have more severe atherosclerosis and calcification
compared to the background strain, partially due to increased blood lipids. LDL
receptors and LDL receptor-related protein-mediated clearance of remnant lipoprotein
maintains the normal cholesterol level in plasma. The clearance of cholesterol-rich
lipoprotein remnant in ApoE-/- mice is compromised, which leads to accumulation of
lipid deposits in the arterial walls, which develop into atherosclerotic plaques as it
progresses [24].Beyond lipid metabolism, ApoE acts as a suppressor of inflammation
as well. It was noted that ApoE-/- mice are prone to endotoxemia and bacterial
16

infection [26, 27]. Under most circumstances, ApoE functions via receptor binding.
Currently there are 7 identified receptors that recognize ApoE as a ligand, all of which
belong to the evolutionarily conserved low-density lipoprotein receptor (LDLR)
family [28].Among them, low density lipoprotein receptor (LDLR), low density
lipoprotein receptor related protein 1 (LRP1), low density lipoprotein receptor related
protein 5 (LRP5),low density lipoprotein receptor related protein 6 (LRP6), very low
density lipoprotein receptor (VLDLR) and apolipoprotein E receptor 2 (ApoER2) are
expressed in VSMCs [29-31].
Studies have explored the relationship between ApoE and osteoblast
differentiation, and showed that ApoE negatively regulates osteogenesis. Interestingly,
ApoE-/- mice were found to have increased bone mass and bone mineral density[32],
but the mechanisms by which ApoE regulates bone formation are not well understood.
Moreover, ApoE appears to be regulated by BMP-2[33] and expressed in the later
stages of osteoblast differentiation [34].

1.3 Canonical Wnt/β-catenin pathway and vascular calcification
The Wnt proteins are a family of secreted glycoproteins that bind to Frizzled
family receptor and various coreceptor(s) depending on which Wnt pathway is
activated[35]. Noncanonical pathways refer to Wnt signaling pathways that do not
involve β-catenin and canonical pathway involves β-catenin[36]. When Wnt/β-catenin
signalling is inactive, β-cateninin cytoplasm is constantly degraded by a destruction
complex which contains Axin, adenomatosis polyposis coli (APC) and glycogen
17

synthase kinase 3 (GSK3). This destruction complex prevents β-catenin accumulation
in cytoplasm. Binding of Wnt ligand(s) to Frizzled and LRP5/6 coreceptor recruits
Axin to the cytoplasmic part of receptor and disrupt the destruction complex. In this
case, β-catenin accumulates in cytoplasm and eventually translocates into the nucleus,
activating transcription of downstream genes [37]. Canonical Wnt/β-catenin pathway
plays a pivotal role in diverse physiological processes such as cell differentiation [38],
cell proliferation [39] and cell-cell adhesion [40]. Wnt/β-catenin pathway plays an
indispensible part in vascular calcification. In vitro studies showed Wnt/β-catenin
pathway is activated when valvular interstitial cells differentiate into ostoblast-like
cells [41]. Wnt/β-catenin is also active in several osteoblast or osteoblast precursor
cell lines including C3H10T1/2 cells and C2C12 cells[42], which implicates its
importance in the regulation of osteogenesis.
As a response to a calcification-inducing stimulus such as high phosphorus
levels, the β-catenin pathway becomes activated, and increased nuclear β-catenin acts
as a transcription factor that leads to enhanced expression of downstream osteogenic
genes, including osteopontin(OPN) and osteocalcin(OCN), resulting in enhanced
calcification[43].

2. Phenotypical Transformation of

Vascular Smooth Muscle Cells

in

Atherosclerosis and Calcification
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2.1 Histology of blood vessels

The arteries and veins consist of three concentric layers: intima, media and
adventitia[44]. The intima comprises a single layer of endothelial cells and a small
amount of connective tissues. The media is the thickest layer of blood vessel walls,
which provides structural support. The media contains vascular smooth muscle cells
(VSMCs), the relaxation and contraction of which determine the elasticity and
diameter of vessels. The adventitia is mainly composed of connective tissue and
fibroblasts.

2.2 Contributions of cellular components to calcification

Once considered as a passive degeneration, vascular calcification turns out to
be an actively regulated process that involves multiple cellular players[4]. Lineage
tracing studies showed vascular endothelial cells might serve as a source of
osoteoprogenitor cells and secret a high level of BMP-2 under the stimulation of
TNF-α, thus promoting osteogenic differentiation of VSMCs[45]. Endothelial cells
are

also

capable

of

mediating

calcification

via

formation

of

microparticles[46].Fibroblasts, when treated with TGF-β1 and elastin degeneration
products, are capable of differentiating into osteoblast-like cells [47]. However, so far
there are few reports that use cultured endothelial cells or fibroblasts to study
calcification, possibly due to the lack of a reproducible and stable way to induce
calcification in these two types of cells.
19

2.3 Induction of VSMC calcification under disease conditions

Vascular

calcification

might

happen

under

conditions

other

than

atherosclerosis, such like chronic kidney disease (CKD) [48]. Vascular calcification is
a common complication in patients with CKD, attributed to an abnormally elevated
phosphate level in blood. Jono et al. found VSMCs treated with increased
concentrations of inorganic phosphate (Pi) in culture became calcified, which is
dependent on a sodium-phosphate cotransporter named Pit-1[49]. Since then, VSMCs
under the stimulus of Pi have been used as an in vitro model to study calcification.
Mature VSMCs express various types of contractile proteins that are important for
their function. As the main cellular component and structural support of the vessel
wall, VSMCs control elasticity of major arteries, while calcified VSMCs greatly
jeopardize the integrity of blood vessels. VSMCs exhibit extensive phenotypic
plasticity and undergo phenotypic switching during development or in response to
environmental cues [50]. When calcification happens, VSMCs gradually lose their
contractility, and transdifferentiating into osteoblast-like cells. The smooth muscle
lineage markers smooth muscle α-actin (αSMA) and smooth muscle 22α (SM22α)
decrease in this process; calcification markers like Runx2, alkaline phosphatase (ALP)
and osteopontin (OPN) are increased.
Besides, calcification can be initiated by membrane bound matrix vesicles
(MVs) produced by living VSMCs and incresed by apoptotic bodies released from
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dying VSMCs. MVs secreted by VSMCs stimulated with calcification-causing factors
contain preformed calcium deposit and calcify extensively[51]. Apoptosis usually
precedes calcification and apoptosis of VSMCs has been shown to promote medial
degeneration and calcification. Apoptotic bodies released by VSMCs act as nucleation
sites for mineralization and concentrate calcium [52].

Figure 1: Inflammation and other pathogenic processes occurring in
atherosclerotic calcification in vivo. Activated macrophages secrete cytokines such
as TNF-α, IL-1β and IL-6, which stimulate vascular smooth muscle cells (VSMCs) to
release more matrix vesicles, accelerating formation of calcium deposits inside the
blood vessels. Apoptotic bodies secreted by apoptotic VSMCs as well as matrix
vesicles act to exacerbate calcification. During atherosclerosis, VSMCs undergo
phenotypic switch from contractile phenotype to synthetic phenotype.
21

Therefore, VSMCs are critical contributors to vascular calcification and
inhibition of osteogenesis or apoptosis of VSMCs might be used as an effective way
to regulate progression of calcification and maintain integrity of arteries.

2.4 Classification of calcification

There have been different opinions about the classification of calcifications. In
general, there are at least 5 types of calcification identified so far: atherosclerotic
calcification, medial calcification, calcific aortic valve disease, calcific uraemic
arteriolopathy and the vascular calcification of end stage renal disease (ESRD), based
on histoanatomic criteria[53].In 1903, Johann Georg Mönckeberg described a type of
calcification called Mönckeberg’s arteriosclerosis, in which calcium deposits are
found in the medial layer of blood vessels. It is still unclear whether Mönckeberg’s
arteriosclerosis is distinct from the five types of calcification mentioned above [54],
but it might be complicated by atherosclerosis[55], diabetes[56] or some other disease.
Since atherosclerosis is characterized by infiltration of lipid and macrophages into the
arterial wall, atherosclerotic calcification invariably associates with these two
elements. Besides, recruitment of VSMCs to the intima of blood vessels is common in
advanced atherosclerotic lesions [57]. Therefore, although the calcium deposits in
atherosclerotic plaques are often observed in the intima, it involves various types of
cells other than intimal endothelial cells. Medial calcification, conversely, is almost
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solely associated with VSMCs compared to intimal calcification.

3. The Ubiquitin-Proteasomal System for Regulation of Protein Homeostasis
3.1. Pathways of protein degradation

Protein turnover stands for the balance between protein synthesis and protein
degradation, which is vital to the normal physiological functioning of cells. There are
two major pathways mediating protein degradation in eukaryotic cells: the lysosomal
proteolysis and ubiquitin-proteasome pathway. The lysosomal proteolysis involves
uptake of proteins by lysosomes, which are organelles enclosed in membranes and
containing digestive enzymes[58]. One major pathway for this uptake is autophagy, in
which

vesicles

from

autophagy-lysosome

endoplasmic
pathway

reticulum
is

fuse

normally

with

lysosomes.

non-selective.

The
The

ubiquitination-proteasome pathway, by contrast, appears to be more involved in
selective and rapid degradation of proteins.

3.2. Ubiquitination

Ubiquitin, a small protein around 8.5 kDa, is universally expressed in almost
all the tissues of eukaryotic organisms. It was discovered by Goldstein and his
colleagues in 1975[59] and further studied by other scientists in 1970s and 1980s[60].
Ubiquitination refers to the process where one or more ubiquitin molecules are
attached to protein residue(s), which affects the degradation, translocation or even
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activity of target proteins. In terms of polyubiquitination-mediated protein
degradation, there are three major enzymes involved: ubiquitin-activating enzyme
(E1), ubiquitin-conjugating enzyme (E2) and ubiquitin ligase (E3). Polyubiquitination
is initiated by E1 via an ATP-dependent reaction, resulting in formation of a thioester
bond between the C-terminal carboxyl group of ubiquitin and the cysteine sulfhydryl
group of E1 enzyme[61]. Then E2, the ubiquitin-conjugating enzyme binds to both
the activated ubiquitin and E1, mediating the transfer of ubiquitin to the active
cysteine residue at the C-terminus of E2 [62]. Afterwards, E3 the ubiquitin ligase,
binds to E2 and substrate protein, creating an isopeptide bond between ubiquitin and
the target protein. Repeating ubiquitination steps add additional ubiquitins to the
substrate protein, forming a polyubiquitin chain[63]. Ubiquitinated proteins are
recognized by the 19S complex of the proteasome and are then unfolded, and digested
by the assembled 26S proteasome[64].
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Figure 2. Ubiquitylation process via E1, E2 and E3 enzymes. The
ubiquitin-activating enzyme (E1) binds to the C-terminus of ubiquitin and activates it,
a process dependent on ATP hydrolysis. The activated ubiquitin is then transferred
from E1 to the conserved cysteine residues of an ubiquitin-conjugating enzyme (E2).
The E2 protein functions together with ubiquitin ligases(E3). E2-E3 complexes bind
to protein substrates and mediate the transfer of ubiquitin to a lysine residue on the
protein substrate. A multiubiquitin chain will be formed after this process is repeated.
The multiubiquitin chain can be recognized by a specific receptor in the proteasome
and subjected to degradation.
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To date, two E1[65] and thirty-five E2 enzymes [66]have been identified from
the human genome, which encodes hundreds of putative E3 ligases, granting
enormous variety to protein substrates. Since ubiquitination regulates degradation of
proteins, it is required to maintain the proteostasis in organisms. Disorders of
ubiquitination lead to accumulation of misfolded proteins in the body, causing a
plethora of diseases, including cancer, metabolic syndromes, inflammatory disorders
and muscle dystrophies [67-69].

3.3 Galactosyltransferase 1-associated protein

All ubiquitin-conjugating (E2) enzymes contain a highly conserved
ubiquitin-conjugating catalytic domain (UBC), which is usually 150-200 amino acids
long [70]. E2s are classified according to the existence of extensions to the catalytic
domain. Class I E2s only contain the catalytic domain, whereas class II, III and IV
E2s have N- or/and C- terminus extensions. These extensions determine the functional
differences between E2s [66].Galactosyltransferase 1-associated protein (GTAP), also
known as Ube2q1, is a member of the class III ubiquitin-conjugating enzyme family.
The Ube2q family has several members, in addition to GTAP, which all consist of a
unique N-terminus and a RWD domain.
GTAP has been shown to interact with and regulates the subcellular
localization of galactosyltransferase 1(GalT1), a protein that potentially modulates
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stem cell pluripotency and differentiation. GTAP is ubiquitously expressed in all
organs and particularly highly expressed in lung, kidney and reproductive organs [71].
Embryonic stem cells have a potent expression of GTAP as well, while differentiated
cells such as endothelial cells and smooth muscle cells express a relatively low level
of GTAP.
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Chapter 2：Hypotheses and Specific Aims

1. Impact of ApoE on atherosclerosis and vascular calcification
Because atherosclerotic plaques frequently become calcified, calcification has
been used as an alternative measure of atherosclerosis. The most commonly used
mouse models to study atherogenesis are the ApoE-/- mice and the LDL receptor
deficient (LDLR-/-) mice, both characterized by hypercholesterolemia. The normal
concentration of serum cholesterol in mice ranges from 80 to 100 mg/dL. ApoE-/mice and LDLR-/- mice fed a chow diet, on the other hand, have an elevated
cholesterol level of 400-500 mg/dL and 175-225 mg/dL respectively [72]. ApoE-/mice spontaneously develop fatty streaks in a proximal aorta at around 3 months old
and aortic plaques at about 8 months old. They tend to have severe atherosclerosis
throughout the arterial tree, especially along the aortic arch due to mechanic stress.
LDLR-/- mice, in comparison, barely have any spontaneously developed
plaques or lesions on the aorta.When fed an atherogenic diet (i.e., high fat diet),
ApoE-/- mice will have abundant plaques and lesions that develop proportionally to
the cholesterol intake, while LDLR-/- mice just show medium plaques and fatty
streaks. Hence it can be seen that ApoE-/- mice are even more susceptible to
hyperlipidemia and atherosclerosis than LDLR-/- mice [73]. The tendency of ApoE-/mice to develop atherosclerosis has been attributed mainly to the raised lipid level in
blood due to loss of ApoE and thus compromised clearance of chylomicrons and
VLDL remnants. However, in recent years, emerging studies have begun to uncover
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new functions of ApoE that contribute to protection against atherosclerosis,
independent of lipid. Although in ApoE-/- mice the lowering of cholesterol level
successfully reduced the severity of atherosclerosis and atherosclerotic calcification, it
is unknown whether ApoE affects other types of calcifications, such as CKD-induced
calcification, which is not directly associated with lipid. Furthermore, among the
identified receptors of ApoE, LRP and LDL receptors prefer lipid-bound ApoE as
their ligand[74]. On the contrary, the VLDL receptor does not require association of
ApoE with lipid for optimal recognition [75]. This indicates lipid-free ApoE might be
sufficient to regulate specific cellular functions.
Culture of macrophages with ApoE upregulated ATP binding cassette
transporter A 1(ABCA1) expression and increased cholesterol efflux via VLDL
receptor and ApoE receptor 2 (ApoER2)[76]. Lipid-free ApoE has antimitogenic
effects on VSMCs, by stimulating Cox-2 gene expression [77]. Moreover,
atherosclerosis is widely known as a chronic inflammatory disease. Inflammation
accompanies atherosclerosis when it goes through different phases. At the early stage
of atheroma development, LDL retained at the intima of blood vessels becomes
oxidized and these oxidized LDL can stimulate the expression of proinflammatory
factors and adhesion molecules like cell adhesion molecule-1 (VCAM-1)[78].
VCAM-1 enables attachment of leukocytes to the vessel walls, which would be
impossible during normal conditions. Macrophages are activated in early
atherosclerotic lesions and produce TGF-β or reactive oxygen species (ROS) which
contribute to calcification [79]. As mentioned above, Runx2, a key regulator of
29

calcification, colocalizes with calcified areas and is expressed by macrophages in
plaque. One secreted cytokine called macrophage colony-stimulating factor (M-CSF)
can be found in plaque as well [80]. M-CSF is not only critical for proliferation and
differentiation of monocytes and macrophages, but also important for osteoblast
survival and function. Therefore, calcification in atherosclerosis represents a
combination of osteogenesis and chronic inflammation. Previous data implicates the
role of ApoE in inflammation suppression by showing that ApoE inhibits the
conversion of macrophages to an antiinflammatory phenotype. In addition, ApoE
inhibits lymphocyte proliferation and production of interleukin-2 (IL-2) [81]. Hence,
to clarify the effect of ApoE on calcification in an environment without intervention
of inflammation or cholesterol, an in vitro calcification system is needed, and
Pi-treated VSMCs will serve as a suitable cellular model to study the calcification
process in the absence of inflammation or lipids. Besides, most of the previous studies
compared the atherosclerotic plaques and vascular calcification in relatively old mice
(30-60 weeks old), when plaques already have formed in the aorta. To date, no firm
evidence has been provided regarding whether mice deprived of ApoE are more likely
to develop vascular calcification before plaques are formed.

2. ApoE regulation of canonical Wnt/β-catenin pathway
The canonical Wnt/β-catenin pathway depends on Frizzled and LRP5/6
coreceptors for activation. Both LRP5 and LRP6 receptors are required for canonical
Wnt/β-catenin signalling to be generated [82]. Interestingly, ApoE is a ligand for
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LRP5 [83]and predicted to bind to LRP6[84] as well. Although ApoE recognition of
LRP5/6 as a heterodimer coreceptor remains unclear, the regulatory effects of ApoE
on Wnt pathway have been observed.
In colon adenocarcinoma cells, ApoE treatment caused β-catenin to localize
mainly in the areas of cell-cell interaction along the cellular membranes, while
untreated cells showed a more diffused pattern of β-catenin distribution[85]. ApoE4,
one of the three isoforms of ApoE, greatly inhibited canonical Wnt signalling in PC12
cells, possibly by binding to LRP1 and thus suppressing expressions of various Wnt
ligands. The other two isoforms of ApoE, ApoE2 and ApoE3 also negatively regulate
Wnt/β-catenin pathway in the presence of LRP5 [86]. Accordingly, it is likely that
ApoE acts as a potential mediator of β-catenin pathway. However, whether ApoE
regulates vascular calcification via canonical Wnt/β-catenin signaling remains
unknown. By using aortic VSMCs isolated from ApoE-/- mice, we will be able to
observe what effects ApoE has on the β-catenin pathway.

3. Regulatory impact of ApoE on GTAP
Although studies have indicated the association of GTAP with several cancers
as well as with reproductive capability [87-89], how GTAP affects the cardiovascular
system remains elusive. However, based on the yeast two-hybrid system database and
membrane based human proteome array, an E3 ligase called STUB1 (CHIP) is
predicted to interact with GTAP[90]. Li et al have shown that STUB1 directly
recognizes and binds to Runx2, a master regulator in osteogenesis. In osteoblasts,
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STUB1 targets Runx2 for proteasome-mediated degradation, thus inhibiting
osteogenic differentiation [91]. Taken together, it is likely that ApoE mediates the
progression of calcification via regulation of GTAP. Our previous data showed lower
expression of GTAP in ApoE-/- mice aortas compared to the background strain.
Furthermore, ApoE induced the expression of GTAP in a time dependent manner.
Whether ApoE regulates calcification via GTAP, however, remains unknown.

Hypothesis: Endogenous ApoE expression serves as a critical factor that prevents
vascular

cell

osteogenesis

and

calcification

during

the

pathogenesis

of

atherosclerosis, by regulating the signal transduction pathways known to be involved
in calcification, such as the canonical Wnt/β-catenin and ubiquitin-proteasome
pathways.Our long-term goal is to define the protective function of ApoE toward
vascular cells and the underlying mechanisms of its regulatory roles in calcification.
The Specific Aims are:

Aim 1: Examine whether ApoE deficiency accelerates vascular cell calcification
in the arterial wall with atherosclerosis.

a). Observe the progression of calcification and expressions of osteogenic genes in
ApoE-deficient aortas by immunohistochemical methods.
b). Perform ex vivo calcification experiments on aortic rings isolated from ApoE-/mice and assess the extent of calcification using a quantitative calcium assay and
Alizarin S staining.
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Aim 2: Study whether ApoE-/- VSMCs express high levels of osteogenic genes
and develop calcification induced by Pi in culture.

a). Treat cultured ApoE-/- VSMCs with Pi to determine whether ApoE-deficiency
exacerbates calcification in vitro.
b). Perform Western blot and qRT-PCR to detect osteogenic genes in ApoE-/VSMCs.
Aim 3: Study whether the regulation of ApoE-dependent calcification in VSMCs
depends on the canonical Wnt/β-catenin pathway.
a). Analyze activation of the Wnt/β-catenin pathway by quantifying the mRNA
levels of β-catenin downstream target genes, as well as observing nuclear
translocalization of β-catenin in ApoE-/- VSMCs incubated with Pi and ApoE.
b). Assess whether the effect of ApoE on calcification in ApoE-/- VSMCs is abolished
when the Wnt/β-catenin pathway becomes constituently activated.
Aim 4:

Determine how GTAP regulates calcification and whether the mediation

of ApoE-dependent calcification partially depends on GTAP.
a) Analyze the level of GTAP during calcification and the severity of calcification as
well as levels of calcification-related genes when expression of GTAP alters.
b) Determine whether GTAP contributes to the impact of ApoE on calcification by
examining the extent of calcification in ApoE-/- VSMCs.
c) Assess whether GTAP affects stability of osteogenic genes by increasing
ubiquitylation.
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Chapter 3：Methods and Materials

1.

Animals
ApoE-/-, GTAP-/-, C57BL/6J and 129sv (used as wild type control animals)

mice were housed and bred under specific pathogen-free conditions in the Animal
Care Facility at the University of Texas Health Science Center and all animal study
protocols were approved by the Animal Welfare Committee of the University of Texas
Health Science Center. The animal experiments were performed following the
guidance of NIH and university regulations.

1.1 Ex vivo calcification assays in mouse aortic rings exposed to phosphate

Male mice of 8-10 weeks old were used. Individual mice were put in sealed
chambers and anesthetized by isoflurane inhalation for 30-60 seconds. We ensured the
mice were anesthetized by lightly pinching the rear foot pad. If a knee jerk was
elicited, the mice were put back into the chamber. After the mouse was anesthetized,
cervical dislocation was performed. Then its skin was disinfected with 70% ethanol
and chest was cut open. Aortas were dissected out from aortic arch to the abdominal
aorta and perivascular fat was removed. Aortas were cut into 2-3 mm length aortic
rings that were rinsed with sterile PBS (HyClone, Logan, UT, Cat# SH3025601)
containing 200 U/mL penicillin and 200 μg/mL streptomycin for at least 5 times.
Aortic rings were then cultured in individual wells of 24-well plates in DMEM
(Sigma-Aldrich, St Louis, MO, Cat#D5796) containing 100 U/mL penicillin, 100
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μg/mL streptomycin,5% FBS and1mmol/L phosphate. Calcification was induced by
culture in high phosphate (2.6mM) media for 9 days. Medium was changed every 3
days. At the termination of the experiment, aortic rings were decalcified with 0.6 M
HCl at 37oC for 24 hours. After decalcification, aortic rings were dried at 37oC and
weighed. The calcium content of the supernatant was determined colorimetrically
with the o-cresolphthaleincomplexone kit from Abcam (Cambridge, UK,Cat#102505),
standardized to the dry weight of aortic rings.

1.2

Histopathology and immunofluorescence of aorta sections
Aortas were harvested from male mice of 50-55 weeks old for

immunofluorescence studies. Freshly dissected aortas were placed onto a pre-labeled
tissue base mold. The entire tissue block was later covered with OCT (Tissue-Tek;
Sakura Finetek USA, Cat#4583) and left on dry ice for 15-20 minutes until it was
completely frozen. Frozen tissue blocks were stored at -80oC until ready for
sectioning. Prior to sectioning, the frozen tissue block was transferred to a cryotome
cryostat (Leica, Buffalo Grove, IL). The tissue block was sectioned to a 5µm
thickness using the cryotome. Sections were placed onto glass slides suitable for
immunohistochemistry. Sections can be stored in a sealed slide box at -80oC for later
use.
For immunohistochemical analysis, sections were dried at 37 oC for 15
minutes and fixed in pre-cooled acetone (-20oC) for fixation for 10 minutes. After
fixation, slides were left at room temperature for 20 minutes or more to allow residual
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acetone to evaporate. Slides were rinsed with PBS 3 times, 5 minutes each. Specimens
were blocked in blocking buffer (5% FBS and 5% BSA in PBS with 0.1% Tween-20)
at room temperature for 60 minutes. Primary antibodies including goat
anti-SM22α1:200 (Abcam, Cat#10135), rabbit anti-αSMA 1:200(Abcam, Cat#5694),
rabbit anti-BMP2 1:200(Abcam, Cat#14933) and goat anti COLI 1:50(Santa Cruz
Biotechnology, Santa Cruz, CA, Cat#59772) were prepared in blocking buffer.
Sections were incubated with primary antibodies at 4oC overnight, followed by
incubation with secondary antibodies TRITC goat anti-rabbit IgG (H+L) conjugate
1:1000( Invitrogen, Waltham, MA, Cat#81-6114) and TRITC rabbit anti-goat
IgG(H+L)1:1000(Invitrogen, Waltham, MA, Cat#31650) at room temperature for 60
minutes. Sections were mounted with mounting medium containing DAPI
(Vectashield, Burlingame, CA, Cat#H-1500). Fluorescence was observed and
photographed with a fluorescent microscope (Nikon Eclipse TE2000-U).

1.3 Alizarin Red S staining of aorta sections

Aortas were harvested from male mice of 50-55 weeks old for Alizarin Red S
staining to detect calcium deposition. Frozen sections of aortas were cut at 4µm, dried
and fixed in acetone as mentioned above; 2% Alizarin Red S staining solution was
prepared freshly by dissolving Alizarin Red S powder in PBS. The pH of Alizarin Red
S staining solution was adjusted to 4.1-4.3 by adding 0.5% ammonium hydroxide and
filtered to remove undissolved powder. Sections were stained with Alizarin Red S
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solution for 10 minutes and washed in 70% ethanol for 15 minutes. Sections were
then observed under the microscope. Calcium deposits appear as orange-red colour
after staining.
2. Cell Culture

2.1 Culture of VSMCs

Aortas were harvested from 5-6 week old mice sterilely. The whole aorta was
rinsed with ice-cold PBS 3 times, and then transferred to warmed DMEM
supplemented with 20% FBS and washed with new medium for 3 times. The aorta
was cut open longitudally, and the endothelium was gently scrapped off with finely
toothed forceps or a scalpel and minced with fine micro-dissecting scissors into
approximately 1 mm2 squares. Following dissection procedures, the tissue pieces were
digested in a conical shaker flask (Costar) with constantly stirring at 37 °C for 8
minutes. After trypsinization, endothelial cells and fibroblasts were dispersed from the
tissue. The tissue pieces were then subjected to a second digestion. Resulting
suspensions were discarded from each digestion procedure. The digestion of the
tunica was terminated by adding DMEM medium supplemented with 20% FBS. The
undigested tissue pieces were evenly distributed into a T25 tissue culture flask (about
15 pieces per aorta, with a distance of 1 cm between individual pieces, no medium
added into the flask), which was put upright at 37 °C into a CO2 incubator with a
humidified atmosphere (5% CO2, 95% air, Thermo, USA) in order to facilitate the
attachment of pieces on the surface of the flask; to remove fibroblasts from the culture,
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the medium was aspirated from the flask and the cells were washed with 25 mL PBS
(per flask). The PBS was aspirated and 7 mL of cold Trypsin-EDTA (0.25%) was
added to the flask. After incubating for 2 min at room temperature the flask was
rapped with the open palm to release the fibroblasts and the Trypsin-EDTA was
aspirated. The cells were washed with 25 mL PBS, the wash aspirated, and 35 mL of
fresh medium was added. The culture was then viewed under the microscope to
determine if the fibroblasts were removed. The new cell culture was then incubated at
37 °C with 5% CO2. The treatment was repeated if fibroblasts proliferated again in the
culture. 4–6 h after inoculation, the flask was put horizontally and then 2 mL of
DMEM containing 20% FBS was carefully added to the flask. The culture medium
was replenished after 72 h and thereafter every 48 h.
Cells were passaged when they reached 80-90% confluence. Prior to splitting
cells, cell culture medium(DMEM containing 10% FBS), PBS and trypsin-EDTA
solution to 37°C by placing all solutions in water bath set at 37°C.All culture medium
was removed from the cell culture flask carefully. Cells were washed with PBS and
trypsin-EDTA was added into the flask. The flask was incubated in the cell culture
incubator (37°C) for 2-3 minutes. Cell morphology was observed under the
microscope. When cells started appearing rounded, the flask was gently tapped to
remove the cells completely from the surface. Cells were washed out from the surface
by pipetting the fresh complete culture medium (5 ml) all over the surface. Certain
volume of the cell suspension, depending on the split ratio, was taken out and added
into a new culture flask. Fresh complete medium was added into the new flask, which
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was put into the 37°C incubator. The remainder of the cells can be discarded, used for
an experiment or for making more culture flasks.

2.2 Treatment of VSMCs

VSMCs from passage 5-10 were used for all the in vitro experiments.
Calcification medium was made by adding NaH2PO4 (pH adjusted to 7.4) into 5%
FBS DMEM medium to obtain a final concentration of 3.6mM inorganic phosphate
(Pi). VSMCs cultured in 5% FBS DMEM (0.9mM phosphate) were used as controls.
To determine β-catenin activation, cells were treated for 1 day. Under other
circumstances, culture medium was changed every 2-3 days for up to 9 days; 6µg/mL
ApoE(Athens Research and Technology, GA, Cat#16-16-120500) and/or 20ng/mL
Wnt3a(R&D Systems, Minneapolis, MN, Cat#1324-WN-002) was added into
medium as needed. To study the effect of ApoE on GTAP expression in VSMCs, cells
were starved with DMEM without serum for 24 hours before treatment. To determine
the stability of Runx2 protein, VSMCs were treated with 80µg/mL cycloheximide
(Sigma-Aldrich, Cat#C1988) for up to 4 hours in regular culture DMEM medium.

2.3 Detection of calcification in cell culture

For detection of calcification in VSMCs, the calcium assay or Alizarin Red S
staining was performed. Procedures are similar to those for aortic sections with minor
modifications. For Alizarin Red S staining, cultured medium was aspirated and cells
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were washed with PBS 3 times; 2.5% glutaraldehyde was used to fix cells at room
temperature for 15 minutes. Then cells were rinsed with PBS (pH adjusted to 4.1-4.3)
3 times and incubated with 2% Alizarin Red S solution at 37°C for 20 minutes.
Excess dye was washed off cells with PBS and staining was observed under the
microscope. For calcium assay, cultured medium was aspirated and cells were washed
with PBS 3 times. Then 0.6M HCl was used to incubate VSMCs at 37°C overnight to
dissolve calcium deposition. The supernatant was taken and the calcium content was
quantified using a colorimetric calcium assay kit as mentioned above. Output was
measured at 575nm and calcium content was calculated using a formula derived from
the standard curve. Cells were washed with PBS, lysed with 0.1 mol/L NaOH/0.1%
SDS. Protein content was determined with the BCA protein assay kit (Thermo
Scientific,Waltham, MA, Cat#23225) and calcium content was normalized to total
protein content.

2.4 Immunofluorescence in VSMCs

VSMCs were seeded and cultured on cover slides in 24-well plates. At the
endpoint of treatment of cells, culture medium was aspirated and cells were washed
with PBS twice. Cells were fixed in 4% paraformaldehyde (PFA) solution diluted in
warm PBS at room temperature for 10 minutes, then rinsed again with PBS 3 times at
room temperature, 5 minutes each; 0.3% Triton X-100 in PBS was applied to
permeabilize cells for 10 minutes with shaking, followed by washing with PBS for 3
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times, 5 minutes each. Cells were incubated with blocking solution (5% FBS and 5%
BSA in PBS with 0.1% Tween-20) at room temperature for 60 minutes. Primary
antibody rabbit anti-β-catenin 1:200(Santa Cruz Biotechnology, Santa Cruz, CA, and
Cat #7963) diluted in blocking solution was used to incubate cells at 4 °C overnight.
Cells were washed with PBS 3 times, 5 minutes each and incubated with
secondary antibody TRITC goat anti-rabbit IgG (H+L) conjugate 1:1000( Invitrogen,
Waltham, MA, Cat#81-6114) diluted in blocking solution at room temperature for 60
minutes. After cells were washed with PBS at room temperature 3 times, 5 minutes
each, DAPI solution (Sigma-Aldrich, St Louis, MO, Cat#62248) was applied to
counterstain cells, which were observed under the microscope.
3. ApoE cDNA Subcloning and Transfection
Plasmid Sport6 that contains mouse ApoE cDNA was constructed by senior
research scientist Michael Wassler and used as the template for ApoE cDNA
subcloning.

Primers

applied

for

amplifying

ApoE

cDNA

are:

5’-CACCCCAATCACAATTGCG-3’ (sense) and 5’-TTGATCTCCTGGGCCAC-3’
(antisense). The PCR reaction conditions are as follows: denaturing at 94°C for 15
seconds, annealing at 52°C for 30 seconds, extending at 68°C for 1 minute. In total,
35 cycles were performed.
After PCR, the reaction mix was separated on 0.8% agrose gel by
electrophoresis. A band of the predicted size was excised under the observation of UV
visualization. The DNA in the cut gel was isolated by using QIAquick Gel Extraction
Kit (Invitrogen, Cat#28704). First, three volumes of buffer QG was added to one
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volume gel and incubated at 50°C for 10 minutes until the gel was completed
dissolved. Then one volume of isopropanol was added and the sample was transferred
to a QIAquick column for spinning. Buffer PE was used for washing the spin tube
pellet, followed by DNA elution with buffer EB.
Isolated DNA was ligated into pcDNA3.1D/V5-His-TOPO cloning plasmid
(Invitrogen, Cat#K900001). The ligation reaction system contained 2μL fresh PCR
product,1μL salt solution, 1μL pcDNA TOPO vector, and 2μL sterile water. The
reaction was mixed gently and incubated at room temperature (22-23°C) for 5
minutes. For transformation, 2μL reaction mixture was added into one vial of One
Shot TOP10 chemically competent E.Coli (Invitrogen, Cat#C4040-10) and mixed
gently. The E.coli was then incubated on ice for 30 minutes, followed by heat shock at
42°C for 30 seconds without shaking. Immediately after heat shock, tubes were
transferred to ice and 250μL S.O.C medium was added into tubes. Tubes were capped
tightly and shaken horizontally (200rpm) at 37°C for one hour; 100-200μL from each
transformation was spread on a prewarmed selective plate and incubated at 37°C
overnight.
Five or more colonies were picked and cultured in 5mL LB medium
containing 100μg/mL ampicillin. Plasmids were isolated using QIAprep Spin
Miniprep Kit (QIAGEN,Venlo, Netherlands, Cat#27104). Bacterial cells were
suspended in 250μL P1 buffer and transferred to a microcentrifuge tube; 250μL P2
buffer was then added and tubes were inverted gently 4-6 times, after which 350μL
N3 buffer was added. Tubes were immediately inverted gently 4-6 times. Samples
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were centrifuged at 13,000rpm for 10 minutes in a table-top microcentrifuge. The
supernatants were applied to a QIAprep spin column by pipetting. Columns were
centrifuged for 1 minute; flow-through was discarded, and then washed with 0.75mL
PE buffer for 1 minute by centrifuging. Samples were centrifuged again for 1 minute
and the column was put in a clean microcentrifuge tube; 25μL EB buffer was added to
the column to elute DNA. The concentration of DNA isolated was measured in a
spectrophotometer (Beckman Coulter). Samples were sent to SeqWright Laboratory
(Houston,TX) for sequencing to confirm that the ApoE gene is cloned and in frame.
The pcDNA3.1D/V5-His-TOPO plasmid that contains the ApoE gene was
designated as ApoE cDNA and the empty plasmid was referred to as the vector. For
transfection, 1.2μg DNA dissolved in EB buffer was diluted with medium without
serum, protein or antibiotics to a total volume of 100μL. Then 4.5μL Attractene
Transfection Reagent (Qiagen, Cat#1051561) was added and mixed by pipetting up
and down. The mixed liquid was incubated at room temperature (15-25°C) for 15
minutes to allow transfection complex formation. The culture medium was aspirated
and 1mL fresh medium was added into each well of 6-well plates. Transfection
complexes were added drop-wise onto the ApoE-/- VSMCs. Plates were swirled
gently to ensure uniform distribution of the transfection complexes. 72 hours after
transfection, VSMCs were passaged into selective medium that contains 800μg/mL
neomycin and the medium was changed every 3 days. When VSMCs reached 90%
confluence, cells were passaged again and experiments were performed.

43

4. Production of Lentivirus Vector for GTAP Overexpression

4.1 GTAP cDNA subcloning

Plasmid pET100D that contains murine GTAP cDNA was constructed by
senior research scientist Dr Michael Wassler and used as the template for GTAP
cDNA

subcloning.

Primers

applied

for

5’-GGAATTCGAGCGGAGCGGAGGATGCAG-3’

PCR

reaction

(sense)

are:
and

5’-CGGGATCCGCCATCTTCCTTTGGGGGTGTGTA-3’ (antisense). PCR product
of predicted size was isolated and later digested by restriction endonuclease EcoRI
and BamHI (New England Biolabs, Ipswich, MA) in 37°C water bath for 1 hour.
Digested PCR product was ligated with p3XFLAG-CMV™-14 Expression Vector
(Sigma-Aldrich, Cat#E7908), which has also been digested by EcoRI and BamHI.
Ligation was performed with DNA Ligation Kit (Takara, Japan, Cat# 6023).
The digested plasmid and PCR product were combined to a total volume of
10μL. One volume of Ligation Mix from the Ligation Kit was added to the DNA
solution and mixed thoroughly. The mixed solution was incubated at 16°C overnight,
then directly used for transformation with One Shot TOP10 chemically competent
E.Coli cells. After transformation, E.Coli cells were cultured on ampicillin selective
plates overnight at 37°C. Colonies were picked and amplified in LB, after which
plasmid DNA was isolated and sequenced to confirm the GTAP gene was successfully
inserted into the p3XFLAG-CMV™-14 vector.
To mutate the active cysteine residue in the C-terminus of GTAP into an
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alanine, the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies,
Santa Clara,CA, Cat#200521) was used. Primers were designed using the online
primer design tool on the Agilent Technologies website.
After constructs were sequenced, wildtype GTAP gene or mutated GTAP
(C351A) with 3XFLAG tag was cloned into CD513B-1 lentivirus expression vector.
Plasmids were isolated from bacterial cells using Plasmid MaxiPrepKit (Qiagen,
Cat#12162).

4.2 Packaging and production of lentivirul particles
293ft cells (ATCC, Manassas, VA, Cat#R700-07)were plated onto 150cm2
plates and cultured in DMEM supplemented with 10% FBS. When cells reach 60-80%
confluence, 4.5μg CD513B-1 empty plasmid or CD513B-1 plasmid that contains
either wildtype GTAP or mutated GTAP was mixed with 45μL pPACKH1 packaging
plasmids (System Biosciences, Los Gatos, CA, Cat#LV500A-1) in DMEM.
Lipofectamine LTX and Plus Reagent (Life Technologies, Cat#15338100) was used to
transfect 293ft cells. After transfection, plates were returned to the cell culture
incubator at 37°C with 5%CO2.
5. Production of Lentivirus for GTAP Knockdown

5.1 Design and Cloning of GTAP shRNA

GTAP shRNA DNA templates (9 in total) were designed using online design
tools siDirect and Darmocon and Ambion, then synthesized by Sigma-Aldrich. The
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following primers were used to amplify desired GTAP shRNA sequence:
5’-GAGCTGGAGCCATGCGAATTC

-3’

(sense)

and

5’-

GACGAGTCGACGAGGTACCGG-3’ (antisense). PCR products of predicted size
were enzymatically digested by restriction endonucleases EcoRI and AgeI, followed
by ligation with pLKO.1 shRNA cloning vector (from Dr Jianping Jin’s lab).Colonies
grown on selection plates which contain ampicillin were picked and sequenced to
confirm the GTAP shRNA sequences are correct.

5.2 Packaging and production of lentivirul particles

Lentiviral particles were produced following similar procedures mentioned
above. 293ft cells (ATCC, Manassas, VA, Cat#R700-07)were plated onto
150cm2plates and cultured in DMEM supplemented with 10% FBS. When cells
reached 60-80% confluence, 4.5μg pLKO.1 empty plasmid or pLKO.1 plasmid that
contains GTAP shRNA was mixed with packaging plasmids (from Dr Jianping Jin’s
lab) in DMEM. Lipofectamine LTX and Plus Reagent (Life Technologies,
Cat#15338100) was used to transfect 293ft cells. After transfection, plates were
returned to the cell culture incubator at 37°C with 5%CO2.
6. Western Blot Analysis

6.1 Sample preparation

VSMCs were first washed with PBS 3 times before Trypsin-EDTA (ATCC,
Cat#30-2101) was added onto culture plates. Plates were incubated in the 37oC
46

incubator for 10-20 minutes until cells detached from the bottom of plates. Cells were
centrifuged at 1000 RPM and were resuspended with PBS. Resuspended cells were
centrifuged again to obtain cell pellets. PBS was aspirated and ice-cold RIPA Lysis
and Extraction Buffer (Life Technologies, Cat#89900) with Protease Inhibitor
Cocktails (Sigma-Aldrich, Cat#p8340) and Phosphatase Inhibitor Cocktails
(Sigma-Aldrich, Cat#5726 and Cat#0044) was mixed with pellets in eppendorf tubes.
Tubes were placed on ice for 15 minutes and centrifuged at 15,000 RPM for 10
minutes. Supernatant was collected and protein concentration of each sample was
measured using BCA protein assay kit (Thermo Scientific). The desired amount of
protein sample was mixed with protein loading buffer and boiled at 98oC for 7
minutes before Western blot was performed.

6.2 Loading and running SDS-PAGE gel

Equal amounts of protein were loaded into each well of all SDS-PAGE gel,
along with Precision Plus Protein Standards molecular weight marker (Bio-Rad, Cat#
161-0374). A constant voltage of 100 V was used to run the gel for 1-2 hours.

6.3 Electrotransferring of proteins from SDS-PAGE gels to membranes

PVDF membranes were activated with methanol for 1 minute, then drained
and equilibrated for 5 minutes in the desired transfer buffer. The filter paper and fiber
pads were soaked in transfer buffer also and the blot ‘sandwich’ was assembled
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according to the instructions provided by Bio-Rad. A constant current of 300mA for 2
hours was used to complete the transfer process. After the transfer, the blot ‘sandwich’
was unclamped and the sheets of filter papers were removed to expose the gel. The
membrane was then taken out and marked properly.

6.4 Immunostaining of target protein bands using antibodies

The membrane was rinsed with PBS for 10 minutes, and then blocked with 10%
BSA in TBS-T for at room temperature for 1 hour. After blocking, the membrane was
incubated with primary antibodies diluted in 3% BSA in TBS-T at 4 oC overnight.
Primary antibodies used include goat anti-SM22α1:5000 (Abcam, Cat#10135), rabbit
anti-αSMA 1:1600(Abcam, Cat#5694), rabbit anti-Runx2 1:1000 (Cell Signaling,
Cat#8486), rabbit anti-GTAP 1:1000 (provided by Dr Michael Wassler), mouse
anti-β-catenin1:1600 (Santa Cruz Biotechnology, Cat#133240), goat anti-lamin B1
1:800

(Santa

Cruz

Biotechnology,

Cat#6216),

mouse

anti-FLAG

1:1000

(Sigma-Aldrich, Cat# F3165), rabbit anti-GAPDH 1:30,000 (Abcam, Cat#8245) and
mouse anti-ApoE 1:2000 (Abcam, Cat#1906). The membrane was washed with
TBS-T 3 times, 10 minutes each and incubated with secondary antibodies diluted in
3% BSA in TBS-T at room temperature for 1 hour. Secondary antibodies used include
goat anti-rabbit IgG HRP 1:20,000 (Santa Cruz Biotechnology, Cat# 2030), goat
anti-mouse IgG HRP 1:5,000 (Santa Cruz Biotechnology, Cat#2005) and donkey
anti-goat IgG HRP 1:5000 (Santa Cruz Biotechnology, Cat#2020). The membrane
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was rinsed with TBS-T 3 times, 5 minutes each. Western blotting ECL substrate
(Pierce, Cat#32106) was used for developing. The membrane was incubated in ECL
working solution for 1 minute at room temperature, after which it was placed in a
plastic sheet protector. An absorbent tissue was used to remove excess liquid and to
carefully press out bubbles from between the plastic protector and the membrane. The
protected membrane was put in a film cassette with the protein side facing up.
Exposure was done using either X-ray films or developing machine (Bio-Rad,
Universal Hood II).
7. Quantitative Reverse Transcription and Polymerase Chain Reaction

7.1 RNA isolation

Culture medium was removed and TRIzol Reagent (Life Technologies,
Cat#15596) was added onto VSMCs. Cells were lysed by pipetting up and down until
no cell pellets are seen and transferred to an eppendorf tube. Then the homogenized
sample was incubated at room temperature for 5 minutes to permit complete
disassociation of the nuclear protein complex; 0.2mL chloroform was added per 1mL
TRIzol Reagent for homogenization. Tubes were capped securely and shaken
vigorously by vortex machine for 15 seconds, after which the sample was incubated at
room temperature for 2-3 minutes. The sample was centrifuged at 12,000 x g for 15
minutes at 4oC.
After centrifugation, the mixture separates into a low red phenol-chloroform
phase, an interphase, and a colorless upper aqueous phase. The aqueous phase was
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removed by angling the tube at 45o and pipetting the solution out. The aqueous phase
was put in a new tube and 0.5mL ice-cold 100% isopropanol per 1mL of TRIzol
Reagent used for homogenization was added and mixed with the aqueous phase. The
mixture was incubated at room temperature for 10 minutes and then centrifuged at
12,000 x g for 10 minutes at 4oC. The supernatant was removed and the RNA pellet
was left in the tube. The pellet was washed with 75% ethanol. The sample was
vortexed briefly and centrifuged at 7,500x g for 5 minutes. The wash was discarded
and the RNA pellet was air-dried for 5-10 minutes. The RNA pellet was resuspended
in RNase-free water by passing the solution up and down through the pipette tip
several times. The sample was incubated in a heat block at 55-60 oC for 10 minutes
and stored at -80oC until use.

7.2 Reverse transcription

For first-strand cDNA synthesis, SuperScript® III First-Strand Synthesis
SuperMix (Invitrogen, Cat#18080-400) was used to convert RNA into first-strand
cDNA. Each component was briefly centrifuged. Up to 5μg total RNA was combined
with oligo(dT) primer, annealing buffer and RNase/DNase-free water in a thin-walled
PCR tube on ice. The mixed solution was incubated in a thermal cycler preheated to
65oC for 5 minutes, then immediately placed on ice for at least 1 minute. The contents
of the tube were collected by brief centrifugation. 2X First-Strand Reaction Mix and
SuperScriptR III/RNaseOUT™ Enzyme Mix were added into the tube on ice to a total
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volume of 20μL. The sample was vortexed briefly to mix by brief centrifugation, and
then incubated at 50oC for 50 minutes. The reactions were terminated at 85oC for 5
minutes and chilled on ice. The reaction was either stored at -20oC or used for PCR
directly.

7.3 Quantitative polymerase chain reaction
To assess gene expression with real-time quantitative PCR,iQ™ SYBR®
Green Supermix (Bio-Rad, Cat#1708880) was mixed with primers, cDNA template
and nuclease-free water in the reaction tube. The reaction mix was centrifuged briefly
in a microcentrifuge. Reaction replicates were loaded into PCR tubes and the reaction
vessels were sealed. For best results, reaction vessels were briefly spun at low speed
to remove any bubbles. The iCycler iQ™ thermocycler (Bio-Rad) was programmed
according to recommended real-time PCR protocol with a melt curve step. The sealed
reaction vessels were placed in the thermal cycler block, and running was started
using a specific PCR protocol. The expression levels of the target mRNAs were
normalized to GAPDH mRNA. The primers for PCR amplication are indicated in
Table 1.
Gene

Sense Primer

Antisense Primer

Type I Collagen

5’-TAGGCCATTGTGTATGC

5’-ACATGTTCAGCTTTGTG

AGC-3’

GACC-3’

5'-CACAATATCAAGGATAT

5'-ACATCAGTTCTGTTCTT

CGACGTGA-3'

CGGGTACA-3'

Alkaline
Phosphatase
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Runx2

Osteopontin

Osteocalcin

Axin2

CyclinD1

Tcf4

GAPDH

5'-TTACCTACACCCCGCCA

5'-TGCTGGTCTGGAAGGGT

GTC-3'

CC-3'

5'-TGGCTATAGGATCTGGG

5'-ATTTGCTTTTGCCTGTTT

TGC-3'

GG-3'

5'-GGGCAATAAGGTAGTGA 5'-GCAGCACAGGTCCTAAA
ACAG-3'

TAGT-3'

5'-CTGGCTCCAGAAGATCA

5'-AATTCGTCACTCGCCTT

CAA-3'

CTT-3'

5'-GCCGAGAAGTTGTGCAT

5'-TGAACTTCACATCTGTG

CTA-3'

GCA-3'

5'-TTTGCCGTCTTCAGTCT

5'-GCATGAAGAAGGAGCT

ACG-3'

AGGG-3'

5'-GGTGAAGGTCGGTGTG

5’-CTCGCTCCTGGAAGATG

AACG-3’

GTG-3’

Table 1. The list and sequence of primers used in quantitative RT-PCR.

8. Reverse transcription and polymerase chain reaction
To confirm ApoE cDNA was successfully inserted into pcDNA plasmid,
RT-PCR was performed using the OneStep RT-PCR Kit (Qiagen, Cat#210210). RNA
isolated from VSMCs transfected with ApoE cDNA or empty plasmid was used and a
master mix solution including RNase-free water, primers, OneStep RT-PCR enzyme
mix and 5XOneStep RT-PCR Buffer was made according to the manual. The
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sequences of primers used are as following: 5’- AGCTCGGATCCAGTACCCTT-3’
(sense) and 5’-CCGCCTCAGAAGCCATAGAG-3’ (antisense). The master mix was
mixed thoroughly and dispensed appropriately into PCR tubes. Template RNA (1μg)
was added to the individual PCR tubes. The PCR reaction conditions are as follows:
reverse transcription at 50°C for 30 minutes, initial PCR activation step at 95°C for 15
minutes. Then 3-step cycling was set as denaturing at 94°C for 15 seconds, annealing
at 52°C for 30 seconds, extending at 72°C for 1 minute. In total, 40 cycles were
performed. After PCR, the reaction mix was separated on 2% agrose gel by
electrophoresis. Bands of the predicted size were visualized using the imaging
machine (Bio-Rad, Universal Hood II).

9. Statistical Analysis

Results are graphed as means±standard deviation (SD). Statistics (t test and
ANOVA) were performed using GraphPad Prism (GraphPad Software, Inc., CA). A
value of P<0.05 was considered statistically significant.
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Chapter 4：Results

1. Increased calcification and pro-osteogenic protein expression in the aortic tissue of
ApoE-/- mice

Aortas were dissected from ApoE-/- and WT mice around 50 weeks old on the
chow diet. Alizarin S staining, which visualizes calcium deposition in blood vessels,
is also greater in ApoE-/- mice while no obvious staining was detected in WT ones
(Figure 3a and 3b). Both ApoE-/- and WT mice have positive SM22α and αSMA
aortic fluorescence staining, with WT mice exhibiting a much more intense signal of
these smooth muscle lineage markers (Figure 3c-3f). We observed weak signal of
calcification marker type I collagen (COLI) in WT mice, while enhanced
immunofluorescence was seen in ApoE-/- murine aortas (Figure 3g and 3h). There
was almost no detectable BMP-2 staining in WT mice; in ApoE-/- mice, positive
signal of BMP-2 fluorescence was found (Figure 3i and 3j). These data indicate that
ApoE-/- mice spontaneously develop more aortic vascular calcification than the
background strain. Ex vivo calcification of aortic rings isolated from ApoE-/- and WT
mice was induced by culture with Pi (2.6mM) in medium for 9 days. There was a
significant difference between calcium levels of WT and ApoE-/- aortic rings after
treatment (ApoE-/- vs. WT: 32.10±9.68 vs. 11.32±6.31μg/mg,p<0.05) (Figure 3k).
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Figure 3. Analysis of calcium contents and biomarkers for smooth muscle and
osteogenesis in the aortic tissues of wild type (WT) and ApoE-/- mice. Alizarin S
staining was used on aortic sections and positively stained areas are of red color (a
and b). Expressions of SM22α, αSMA, COLI and BMP-2 were detected by
immuofluorescence analysis in the aortas, COLI indicates type I collagen (c-j). k:
Calcium levels of explanted murine aortic rings after culture in medium containing
2.6mM Pi. n=5 per group.Bars indicate mean±S.D.*p<0.05.
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2. ApoE-/- VSMCs are prone to Pi-induced calcification in vitro
VSMCs grown in DMEM media with or without Pi (3.6mM) for up to 9 days
were stained with Alizarin Red S (2%) for calcium content determination. In cell-free
media, there was no detectable calcium precipitation in the wells with VSMC (data
not shown), indicating the appearance of calcium deposition in cell culture did not
result from chemical reaction of phosphate and components in culture medium.
Neither wild type (WT) nor ApoE-/- VSMCs calcified in regular culture medium, but
both showed accumulation of calcium deposit when cultured in calcification medium
containing 3.6mM phosphate for up to 9 days (Pi). However, ApoE-/- VSMCs
exhibited a more drastic increase of calcium mineralization than WT VSMCs in a
time dependent manner, manifested by Alzarin S staining (Figure 4a-4h) and calcium
assay (Figure 4i).The protein expression level of smooth muscle lineage markers
SM22α and αSMA were decreased in ApoE-/- VSMCs, though no significant
difference of Runx2 expression was detected between ApoE-/- and WT cells (Figure
5a-5d). The mRNA level of calcification marker COLI is upregulated, when
calcification suppressor OPN(osteopontin) is downregulated in ApoE-/- cells(Figure
6a and 6b).
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Figure 4 .Analysis of calcium content in WT and ApoE-/- aortic VSMCs
incubated with or without Pi. Aortic VSMC from WT and ApoE-/- aortas were
incubated in the media containing 3.6mM Pi for up to 9 days, stained with Alizarin
Red S for 10 minutes at 37oC, and then visualized under a Nikon microscope. a-h,
Calcification in WT and ApoE-/- VSMCs incubated with Pi for 0,3,6 and 9 days.
Images were taken using a 10x objective.i, Colorimetric calcium assays based on the
chemical reaction between calcium and

o-cresolphthaleincomplexone. n=4,
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*

p<0.05,**p<0.01.

Figure 5. Western blot analysis of smooth muscle-specific and osteogenic
biomarkers in wild type and ApoE-/- VSMCs. Protein expressions of SM22α,
αSMA and Runx2 are compared between ApoE-/- and WT aortic VSMCs by
immunoblotting. A representative western blot is shown at the top (a). Bars indicate
fold change (n=3) determined by densitometry of target gene bands, normalized to
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GAPDH (b-d). *p<0.05.

Figure 6. qRT-PCR analysis of osteogenic transcripts in WT and ApoE-/- VSMCs.
Expression of COLI and OPN mRNA was analyzed by qRT-PCR. a, qRT-PCR for
COLI, and b, qRT-PCR for OPN. Data represents means±S.D. (n=3). *p<0.05.
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3. Overexpression of ApoE alleviates calcification in cultured VSMCs
To further confirm that ApoE regulates the calcification process, we
reintroduced ApoE into ApoE-/- VSMCs via plasmid transfection; these cells were
designated as ApoE cDNA group. Empty vector transfected ApoE-/- VSMCs were
referred to as the mock group. Calcification experiments were performed on stably
transfected cells. The existence of ApoE gene in VSMCs was confirmed by RT-PCR
and western blot (Figure 7a and 7b). When incubated with 3.6mM Pi in medium,
ApoE cDNA transfected VSMCs showed less calcification than the mock group,
especially on day 6 and day 9 of treatment (Figure 8a-8i). ApoE deficient VSMCs
express a lower basal protein level of SMC markers SM22α and αSMA, as well as
decreased mRNA expression of osteogenesis inhibitor OPN. A higher level of type I
collagen mRNA was detected in ApoE-/- VSMCs also. Runx2 protein levels were not
significantly different between either ApoE-/- and WT, or ApoE-/- and ApoE cDNA
transfected VSMC groups（Figure 9 and Figure 10）,which is consistent with data
obtained from ApoE-/- and WT VSMCs.
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Figure 7. RT-PCR and Western blot analysis for ApoE expression in ApoE-/VSMCs transfected with murine ApoE cDNA. ApoE-/- VSMCs were either
transfected with ApoE cDNA or plasmid vector (mock) and incubated in selection
medium for isolating successfully transfected cells. The expression of ApoE in
transfected VSMCs was confirmed by RT-PCR (a) and western blot of the culture
medium (b).
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Figure 8. Calficiation assays in ApoE-/- VSMCs transfected with or without
ApoE cDNA. Alizarin Red S staining of VSMCs was observed under microscope
using a 10X objective.Calcification appeared as scattered deposits (a-h).Calcium
assay was performed to quantify the calcium content in transfected VSMCs (n=4).
The ApoE cDNA group of VSMCs showed significantly lower calcium content than
mock cells on day 6 and day 9 of Pi treatment (i). *p<0.05 vs. ApoE cDNA group.
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Figure 9. Western blot analysis of smooth muscle-specific(αSMA and SM22) and
osteogenic (Runx2) biomarker in ApoE-transfected and mock VSMCs. ApoE-/VSMCs transfected with either vector (mock) or ApoE cDNA-expressing plasmid
were collected. The protein expression of SM22α, αSMA and Runx2 in the ApoE
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cDNA transfected group and the mock group is detected by immunoblotting (a). Bars
indicate fold change (n=3) determined by densitometry of target gene bands,
normalized to GAPDH (b-d). *p<0.05.
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Figure 10. Analysis of the mRNA expressions of smooth muscle lineage markers
and osteogenic genes in transfected VSMCs. Gene expressions of COLI and OPN
on mRNA levels were analyzed by quantitative reverse transcription–polymerase
chain reaction in ApoE-/- VSMCs transfected with either vector (mock) or ApoE
cDNA-expressing plasmid. a.qRT-PCR of COLI. b. qRT-PCR of OPN. Genes were
indicated on the left side, and bars show normalized fold changes (n=3).*p<0.05.
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4. Treatment with exogenous Apolipoprotein-E protein inhibits calcification of
VSMC cultured from the aortas of ApoE-/- mice

Our previous studies indicated that ApoE-/- VSMCs are more susceptible to
phosphate (Pi)-induced calcification than wildtype (WT) cells and the inhibitory
effect on calcification of ApoE-/- VSMCs was more obvious than that of the WT
group (data not shown). Therefore, ApoE-/- VSMCs was selected as the in vitro
model to explore the function of ApoE during calcification. Accumulation of calcium
deposits in ApoE-/- VSMCs was detected by calcium assay after 9 days of incubation
in calcification medium containing an elevated concentration of phosphate (3.6mM),
compared with cells maintained in control medium. The addition of human
apolipoprotein E (6µg/mL) into the culture medium significantly alleviated
calcification in ApoE-/- VSMCs (Pi vs. Pi+ApoE: 227.78±19.97 vs. 153.83±30.76
µg/mg, n=5, p<0.05) (Figure 11a). Alizarin S staining also shows positively-stained
red areas in ApoE-/- VSMCs under Pi treatment, which could not be seen in the
control group of cells. ApoE, on the other hand, greatly shrank these areas (Figure
11b-11d).
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Figure 11. Analysis of calcification in VSMCs cultured from aorta tissues from
ApoE-/- mice. ApoE-/- VSMCs were cultured in medium containing 3.6mM Pi for 9
days to mineralize. Colorimetric calcium assay was performed to quantify calcium
level in untreated cells, cells treated with Pi, and cells treated with both Pi and ApoE
protein (6µg/mL)(a). Alizarin S staining was applied to visualize calcium deposits
under microscope using a 10X objective (b-d). **p<0.01 vs. control.#p<0.05 vs. Pi.

67

5. Exogenous ApoE treatment inhibits osteoblast-like phenotype transformation of
ApoE-/- VSMCs
When induced to calcify, the protein level of smooth muscle marker SM22α in
ApoE-/- VSMCs decreased, while Runx2 protein expression was enhanced, shown by
western blot. ApoE attenuated these effects by decreasing the Runx2 protein level to
control values, as well as inhibiting the loss of SM22α during calcification (p<0.05)
(Figure 12).

Besides, mRNA levels of calcification markers including alkaline

phosphatase (ALP), Runx2, osteopontin (OPN) and osteocalcin (OCN) all increased
greatly compared to the control group. ApoE protein dramatically reduced the
expression of these osteogenesis-related genes in Pi treated VSMCs. Nevertheless,
there was still a significant difference of ALP mRNA level between calcifying cells
treated with ApoE and control cells (p<0.01) (Figure 13), which suggests that ApoE
failed to completely prevent the alternation of ALP as a response to Pi. These findings
imply that ApoE is capable of partially reversing the osteoblast-like phenotypic
change of VSMCs during calcification.
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Figure 12. Western blot analysis of SM22 and Runx2 expression in ApoE-/VSMCs. Cells were incubated in regular control, calcification-inducing (3.6mM Pi),
and Pi plus native human ApoE protein(6µg/mL) for 9 days,and then total proteins
collected for Western blot analysis.a-c，Western blot for SM22α, Runx2 and GAPDH.
A representative western blot is shown at the top. Bars indicate fold change (n=3)
determined by densitometry of bands, normalized to GAPDH. *p<0.05 vs.
control.**p<0.01 vs. control.#p<0.05 vs. Pi.
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Figure 13. qRT-PCR analysis of calcification biomarkers in ApoE-/-VSMCs with
purified human ApoE protein in Pi-containing media. Cells were incubated either
in regular medium or in calcification medium (3.6mM Pi) with or without ApoE
protein (6µg/mL) for 9 days. mRNA expressions of calcification markers including
ALP,

Runx2,OPN
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OCN

were

analyzed
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quantitative
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transcription-polymerase chain reaction(a-d). Bars indicate normalized fold change
(n=5). ALP indicates alkaline phosphatase; OPN, osteopontin; OCN, osteocalcin.
*p<0.05 vs. control.**p<0.01 vs. control.#p<0.05 vs. Pi.##p<0.01 vs. Pi.
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6. The Wnt/β-catenin pathway is involved in ApoE’s attenuation of calcification

The activation of the canonical Wnt/β-catenin pathway leads to the
translocation of β-catenin into the cell nucleus. Western blotting was used to assess
the presence of β-catenin in nuclear extracts from VSMCs. Incubation with Pi
dramatically increased the amount of intranuclear β-catenin. However, when VSMCs
were treated with Pi and ApoE together, expression of β-catenin in nuclear was
suppressed (Figure 14a and 14b). Consistently, immunofluorescence revealed that
β-catenin mainly resided in the cellular membrane and cytoplasm in control cells,
while Pi treated VSMCs showed strong β-catenin staining in the nucleus. ApoE
reduced the nuclear proportion of β-catenin, suggesting that ApoE inhibited canonical
Wnt/β-catenin pathway activation induced by Pi (Figure 14c). The involvement of
Wnt/β-catenin pathway was further confirmed by qRT-PCR of β-catenin target genes,
including Axin2, CyclinD1 and Tcf4 (Figure 15), which were all increased during
calcification (p<0.05). However, Pi failed to stimulate the expression of these genes to
rise when cells were subject to ApoE treatment. To clarify whether ApoE still protects
ApoE-/- VSMCs from calcification under conditions in where Wnt/β-catenin pathway
is constitutively activated, we used the canonical β-catenin activator Wnt3a to treat
cells. Under the calcifying condition, VSMCs exhibited a 1.4-fold increase in
mineralization level when Wnt3a was added into the medium (Pi vs. Pi+Wnt3a:
176.45±30.21 vs. 249.35±61.72 µg/mg, n=4, p<0.05); ApoE lost the ability to
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attenuate calcification in the presence of Wnt3a. Alizarin Red S also showed enlarged
areas of positive staining in Wnt3a treated VSMCs, regardless of whether ApoE was
applied to cells or not (Figure 16).
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Figure 14 ． Western blot and immunofluorescence analysis of β-catenin
expression in ApoE-/- VSMCs treated with human ApoE. Cells were grown in
regular medium or in calcification medium (3.6mM Pi) with or without ApoE protein
(6µg/mL) for 24 hours. a and b, Western blot using nuclear protein extracts from
VSMCs. A representative western blot is shown at the top. Bars indicate fold change
(n=3) determined by densitometry of bands, normalized to lamin B. c, Subcellular
localization of β-catenin (red) visualized by immunofluorescence. Nuclei were
counterstained with 4, 6-diamidino-2-phenylindole (DAPI)(blue). Scale bar=2.5µm. d,
Cells from 3 random fields under each condition were scored for β-catenin
localization and analyzed by the Pearson’s coefficient.Bars indicate fold changes.
**p<0.01 vs. control.##p<0.01 vs. Pi.
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Figure 15.qRT-PCR assessment of β-catenin target gene expression in ApoE-/VSMCs. Cells were incubated either in regular medium or in calcification medium
(3.6mM Pi) with or without ApoE protein (6µg/mL) for 24 hours.a, Axin2; b, Cyclin
D1; and c, Tcf4. Data represents means±S.D., n=5. *p<0.05 vs. control; and #p<0.05
vs. Pi.
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Figure 16. Calcification of VMSCs treated with Wnt3a and/or ApoE protein.
ApoE-/- VSMCs were incubated either in calcification medium (3.6mM Pi) or in
calcification medium with Wnt3a (20ng/mL) and/or ApoE protein (6µg/mL) for 9
days a,Calcium assay of calcium deposits in VSMCs (n=4).b-d, Alizarin Red S
staining was observed under microscope using a 10X objective.*p<0.05 vs. Pi.
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7. ApoE deficiency attenuates expression of GTAP in murine aortas and aorta-derived
VSMCs.

The expression of GTAP in ApoE-/- and WT aortas and VSMCs was detected
by Western blot. Protein was extracted from either murine cells or aortas. A stronger
signal of GTAP was detected in WT aortas than in ApoE-/- ones (Figure 17a), which
indicates that wild type mice generally have higher protein expression of GTAP in
aortas than ApoE-/- mice. Similarly, aortic smooth muscle cells that are
ApoE-deficient exhibit lower GTAP expression than WT VSMCs (Figure 17b).
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Figure 17.Western blot analysis of GTAP expression in murine aortas and
aorta-derived VSMCs. Total proteins extracted from aortic tissues and VSMC
cultured from aortas were used to assess the protein level of GTAP by Western blot.(a)
Western blot for GTAP and GAPDH in aortic tissues; and (b)Western blot for GTAP
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and GAPDH in VSMC cultures.Bars represent means ±SD; n = 4 per group for aortas
and n=3 for VSMCs. *p<0.05 vs.WT, **p<0.01 vs. WT.
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8. Human plasma ApoE induces GTAP in VSMCs from ApoE-/- but not wild type
mice.

Both ApoE-/- and WT VSMCs were treated with 6μg/mL human ApoE for up
to 4 hours, after 24 hours starvation in serum-free medium. Western blot was
performed to detect GTAP expression level. WT VSMCs showed a clear band of the
predicted size of GTAP (46kDa), even in cells without ApoE treatment, indicating that
WT VSMCs have a potent expression of GTAP protein. Moreover, GTAP band
instensity in WT VSMCs did not change significantly after ApoE treatment for up to 4
hours, which suggests that the level of GTAP was not dramatically affected by ApoE
in WT VSMCs (Figure 18a). ApoE-/- VSMCs, on the other hand, exhibited barely
detectable GTAP protein expression at the absence of ApoE in culture medium. In
ApoE-/- VSMCs treated with ApoE, GTAP expression increased in a time-dependent
manner (Figure 18b); a statistically significant difference was found between
untreated cells and cells treated with ApoE for 2 hours or 4 hours.
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Figure 18. Western blot analysis of GTAP expression in wild type and ApoE-null
VSMCs treated with or without purified human ApoE protein. VSMCs were
incubated with DMEM control medium (Ctrl) or with 6μg/mLApoE for up to 4 hrs.a,
WT VSMCs; and b, ApoE-/- VSMCs. GTAP band intensity was normalized to
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GAPDH. Bars represent means ± S.D; n = 3 per group. *p<0.05 vs.ctrl, **p<0.01 vs.
Ctrl.
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9. GTAP decreases in wildtype (WT) VSMCs during calcification

To determine whether GTAP expression alters in the process of calcification,
either WT or ApoE-/- VSMCs were treated with 3.6mM Pi for up to 9 days. Cells
were collected at various time points and Western blot was performed to detect GTAP
expression. Interestingly, in WT VSMCs, the intensity of GTAP protein band
decreased in a time-dependent manner; densitometry together with statistical analysis
showed GTAP expression in cells incubated with 3.6mM Pi was significantly lower
than cells cultured in regular medium(Figure 19a). In ApoE-/- VSMCs, GTAP levels
almost remained unchanged 3 days, 6 days, and 9 days after treatment with Pi started
(p>0.05)(Figure 19b).
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Figure 19. Western blot analysis of GTAP in VSMCs incubated with Pi. Wildtype
or ApoE-/- VSMCs were incubated with 3.6mM Pi for up to 9 days. Total proteins
extracted from VSMC cultured from aortas were used to assess the protein level of
GTAP by Western blot in WT (a) and ApoE-/- (b) VSMCs. Bars represent means ±
SD; n = 3 per group. *p<0.05 vs.pre.
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10. Calcification in VSMCs that overexpress GTAP

Lentiviral expression plasmid CD513B-1 that contains 3XFLAG GTAP
cDNA was constructed for transduction of VSMCs. Because GTAP functions as an E2
ubiquitin-conjugating enzyme thorough the active cysteine amino acid residue (C351)
in the C terminus, another construct that expresses GTAP with the active cysteine
mutated to alanine was used as well to study the relationship of GTAP-mediated
ubiquitination and calcification. CD513B-1 also encodes green fluorescence protein
(GFP) and puromycin selection marker. Both WT and ApoE-/- were infected with
lentiviral particles and incubated in selective culture medium for 3 weeks in order to
obtain cells stably overexpressing GTAP. Cells were observed under a fluorescent
microscope and green fluorescence was detected in infected WT and ApoE-/- VSMCs
(Figure 20a-20f), which indicates successful infection. In both cells, the vector group
showed the strongest fluorescence among all the groups. Cells overexpressing
wildtype GTAP (designated as GTAPWT) had a weaker signal compared to cells
overpressing mutated GTAP (designated as GTAPC351A). Expression of 3XFLAG
GTAP was confirmed by Western blot (Figure 20g and 20h).
Then VSMCs were treated with 3.6mM Pi for 9 days to induce calcification. In WT
VSMCs, overexpression of GTAPWT or GTAPC351A decreased calcification compared
to vector group; GTAPWT showed more dramatic suppression of cellular
mineralization than GTAPC351Agroup, reflected by Alizarin Red S staining ( Figure
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21a-21c) and calcium assay (Figure 21d). In ApoE-/- VSMCs, no significant
difference in the level of calcification was found between vector, GTAPWT and
GTAPC351A groups of cells in response to Pi incubation (Figure 21e-21h).
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Figure 20. Immunofluorescence and Western blot analysis of VSMC infected by
GTAP-expressing lentivirus. Immunofluorescence images of wildtype (a-c) and
ApoE-/-(d-f) VSMCs infected by lentivirus that express vector only, wildtype
GTAP(GTAPWT), or mutated GTAP (GTAPC351A) were observed under fluorescence
microscope (400X).Western blot was performed on lysis of WT (g) and ApoE-/-(h)
VSMCs. GAPDH was used as the loading control.
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Figure 21. Assays for calcification in VSMCs infected with wild type and mutant
GTAP. Wildtype(WT) or ApoE-/- VSMCs that overexpress wildtype GTAP
(GTAPWT ) or mutant GTAP (GTAPC351A ) were incubated with 3.6mM Pi for 9 days.
Alizarin Red S staining of WT (a-c) and ApoE-/- (e-g) VSMCs were performed to
visualize calcium deposits, which were observed under microscope using a 10X
objective. Calcium assay of WT (d) and ApoE-/- VSMCs (h) were applied to quantify
calcium content.

Bars represent means ± SD; n = 3 per group. *p<0.05

vs.vector.**p<0.01vs. vector. ##p<0.01 vs.GTAPWT.
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11. Increased calcification in the aortic tissue of GTAP-/- mice

Aortic tissues were dissected from 8-10 weeks old male mice of 129sv
background. Aortas were collected from wildtype 129sv mice (GTAP+/+),
heterozygous GTAP-deficient mice (GTAP+/-） and GTAP knockout mice (GTAP-/-).
Part of aortic tissues were lysed and used for Western blot; GTAP protein expression
level was assessed in these three groups of samples. There was barely detectable
GTAP in aortic tissues from GTAP-/- animals, while GTAP+/- and GTAP+/+ mice
showed visible GTAP band. The expression of GTAP in GTAP+/+ aortas was more
potent than GTAP+/- ones (Figure 22a). Meanwhile, some aortic tissues were cut into
aortic rings and placed onto plates. Culture medium with 2.6mM Pi was used to
induce calcification of aortic rings for 9 days. After treatment, calcium assay was
performed to assess calcification, standardized to dry weights of aortic rings. Aortic
rings from GTAP-/- mice showed significantly higher calcium content than aortic
rings from GTAP+/+ or GTAP+/- mice, suggesting GTAP deficiency renders aortic
rings more susceptible to Pi-induced calcification. No obvious difference was
observed in calcification between GTAP+/+ and GTAP+/- aortic rings (Figure 22b).
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Figure 22. Western blot analysis of GTAP expression and calcification assays
inmurine aortic rings incubated with Pi ex vivo. Aortas were dissected from
wildtype 129sv mice (GTAP+/+), heterozygous GTAP-deficient mice (GTAP+/-） and
GTAP knockout mice (GTAP-/-). Aortas were either collected for immunoblotting or
cut into rings and incubated in calcification medium (2.6mM Pi) for 9 days. a.
Western blot analysis of GTAP expression in aortas without Pi treatment.
b.Calcification of murine aortic rings in response to elevated phosphate, bars
represent means ±SD; n=4 per group.*p<0.05 vs.GTAP+/+.#p<0.05 vs. GTAP+/-.
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12. Decreased expression of GTAP in VSMCs exacerbates calcification

In order to knock down GTAP in VSMCs, a pLKO.1 lentiviral expression
vector that contains a sequence which targets GTAP was constructed. Lentiviral
particles were produced by transfection of 293ft cells with expression vector together
with packaging plasmids. VSMCs were infected with virus expressing either negative
shRNA that does not target any known sequence in murine genome, or GTAP shRNA.
To achieve stable lentivirus-delivered RNA interference (RNAi), VSMCs were
selected by the addition of puromycin and GTAP expression was analyzed by Western
blot (Figure 23a). Compared to cells infected with negative shRNA control, GTAP
was drastically reduced in cells infected with lentivirus expressing GTAP shRNA.
Then infected VSMCs were incubated with 3.6mM Pi to induce calcification. Level of
calcification was assessed by Alizarin Red S staining (Figure 23b and 23c) and
calcium assay (Figure 23d). In GTAP knockdown VSMCs, more positive Alizarin
Red S staining was observed in cell culture and higher calcium content was detected,
which indicates inhibited expression of GTAP worsened calcification in VSMCs
treated with elevated level of Pi.
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Figure 23.Western blot analysis of GTAP and calcification assays in murine
VSMCs treated with shRNA.Wildtype VSMCs infected with lentivirus that express
either negative shRNA or GTAP shRNA were treated with 3.6mM Pi to induce
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calcification for 9 days. a.Before Pi treatment, western blot analysis of GTAP
expression in VSMCs that express negative shRNA or GTAP shRNA was performed
to confirm the knockdown of GTAP protein level. Alizarin Red S staining (b and c)
and calcium assay (d) of GTAP knockdown VSMCs after incubation with 3.6mM Pi
for 9 days. Bars represent means ±SD; n=3 per group.*p<0.05 vs. negative shRNA.
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13. Increased expression of GTAP upregulates smooth muscle markers in VSMCs

Wildtype VSMCs that stably express lentiviral vector only or lentiviral vector
that contains either GTAPWTor GTAPC351A cDNA were collected and Western blot
was performed to detect expressions of osteogenetic gene Runx2, as well as smooth
muscle lineage markers αSMA and SM22α. VSMCs that overexpress GTAPWT
expressed higher levels of αSMA and SM22α than VSMCs that express vector.
Overexpression of GTAPC351A enhanced, slightly but not significantly, expression of
αSMA in VSMCs. The expression of SM22α was elevated in VSMCs expressing
GTAPWT or GTAPC351A, in comparison to vector group. A weaker signal of Runx2 was
detected when cells overexpress GTAPWT( Figure 24).
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Figure 24. Western blot analysis of smooth muscle and osteogenic lineage
biomarkers in VSMCs transduced with wild type and mutant GTAP. VSMCs that
expresses wildtype GTAP(GTAPWT) or mutated GTAP(GTAPC351A)

via lentiviral

infection were lysed and Western blot was performed. VSMCs expressing vector were
used as the control. a.A representative Western blot of αSMA, SM22α and Runx2 is
shown on top. b. Bars indicate fold change determined by densitometry of target gene
bands, normalized to GAPDH. n=3 per group. *p<0.05 vs. vector.
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14. Decreased expression of GTAP downregulates smooth muscle markers in VSMCs.

Wildtype VSMCs that stably express negative shRNA which does not target
any known sequence in murine genome or GTAP shRNA via lentiviral infection were
lysed and Western blot was performed. Expressions of smooth muscle lineage
markers αSMA and SM22α were downregulated in VSMCs expressing GTAP shRNA
compared to negative shRNA-expressing cells. However, knockdown of GTAP with
lentiviral shRNA greatly enhanced the expression of Runx2, the master regulator of
osteogenesis (Figure 25).
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Figure 25.Analysis of expressions of smooth muscle lineage markers and
osteogenic gene in GTAP knockdown VSMCs. VSMCs that expresses negative
shRNA or GTAP shRNA via lentiviral infection were lysed and Western blot was
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performed. a. A representative Western blot of αSMA, SM22α and Runx2 is shown
on top. b. Bars indicate fold change determined by densitometry of target gene bands,
normalized to GAPDH. n=3 per group. *p<0.05 vs. negative shRNA.
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15. Augmentation of Runx2 expression by knockdown of GTAP with GTAP-specific
shRNA

To determine the role of GTAP in Runx2 degradation, VSMCs that stably
express either negative shRNA controls or GTAP shRNA were incubated with
cycloheximide (CHX) to inhibit protein synthesis for up to 4 hours. Western blot
analysis of total proteins extracted from VSMCs with or without shRNA suppression
of GTAP (Figure 26) showed different patterns of Runx2 protein expression. In
control cells with negative shRNA, Runx2 declined gradually with prolonged
incubation with CHX, suggesting that Runx2 pre-existing in the cells was in the
process of degradation. However, when GTAP was knockdown in VSMCs with
specific shRNA, the levels of Runx2 expression only decreased slightly during the
entire 4-hour period of time, compared to control cells. This result manifests that in
the cells with shRNA-mediated decreased expression of GTAP, half-life of Runx2 is
prolonged, which suggests the degradation of Runx2 depends on GTAP expression.
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Figure 26. Western blot analysis of Runx2 level in VSMCs with decreased
expression of GTAP. GTAP knockdown VSMCs were treated with cycloheximide
(CHX) in culture for up to 4 hours VSMCs that express negative shRNA were used as
control cells. a. Inhibition of protein synthesis by CHX and western blotting showing
the expression of Runx2 at the indicated times (hrs). b. The half-life of Runx2 was
estimated based on the intensity of Runx2 bands at different time points shown in a.
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16. The requirement of the Cysteine351 residue in the ubiquitin-binding site of GTAP
for Runx2 Degradation in VSMCs

To determine whether the active cysteine residue in the ubiquitin-binding site
of the C-terminus of GTAP plays a critical role in Runx2 degradation, the viral
vectors with GTAP wild type or a mutant with the cysteine residue replaced by
alanine at the 351 position of GTAP was delivered to VSMCs. The cells
overexpressing wild type GTAP (GTAPWT) or mutant GTAP (GTAPC351A) were then
treated with CHX. We found that Runx2 protein levels were gradually decreased in
VSMCs that overexpress GTAPWT in the function of CHX treatment up to 4 hours. By
contrast, cells with overexpression of the mutant GTAPC351Aexhibited higher levels of
Runx2 compared to VSMCs with GTAPWT during the when treated with the same
amount of CHX for the same period of time (Figure 27). This observation suggests
that Runx2 degradation was compromised in VSMCs with GTAPC351A mutant
expression, and an active cysteine (C351) is required for Runx2 degradation.
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Figure 27. Western blot analysis of Runx2 level in VSMCs with GTAP
overexpression. VSMCs that overpress either the wildtype form of GTAP (GTAPWT)
or mutant GTAP (GTAPC351A) were incubated with cycloheximide (CHX) in culture
for up to 4 hours. a. Inhibition of protein synthesis by CHX and western blotting
showing the expression of Runx2 at the indicated times (hrs). b. The half-life of
Runx2 was estimated based on the intensity of Runx2 bands at different time points
shown in a.
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Chapter 5：Discussion
Vascular calcification represents a common biomarker of pathological changes in
the arterial wall with atherosclerosis. In the first part of this study, we conducted
experiments to address the issue of molecular regulation of calcification. Many reports
published by other research groups have demonstrated that ApoE knockout mice
develop severe atherosclerosis with mass calcification [54-56]. However, it is not clear
if the vascular atherosclerotic lesions with calcification develop as a consequence of
other pathobiological conditions, such as hypercholesterolemia, inflammation and/or
apoptosis. Here, in the first part of this study, we show experimental evidence that
ApoE serves as a key factor in regulation of VSMC calcification independently from
the above risk factors. We observed that the deficiency of ApoE accelerates vascular
smooth muscle cell calcification, using both in vivo and in vitro models.
Under normal chow diet, ApoE-/- mice develop hypercholesterolemia and severe
atherosclerotic plaques. They usually develop calcification in the regions surrounding
advanced plaque tissues, often giving the impression that VC occurs secondarily to
plaque generation. However, in our study, we show that ApoE-/- aortic tissues with no
or minor atherosclerosis can have increased calcification, indicating that calcification
may be a separate or independent event from atherosclerotic lesion development. This
notion is supported by our finding that VSMC cultured from ApoE-/- mice in normal
media with no high cholesterol contents and inflammation responses can develop
severe calcification.
Aortic calcification usually occurs in mice in an age-dependent manner [92]; VC
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will be accelerated under the stimuli of chemicals like vitamin D or nicotine [93, 94].
Here in our study, VSMC calcification develops in a microenvironment lacking those
stimuli, but containing inorganic phosphate. Therefore, the tendency to form
calcification in ApoE-/- mice is likely due to the predisposed expression pattern of
calcification-related genes in ApoE-/- cells in the blood vessels. Apart from the
susceptibility to have atherosclerotic calcification, ApoE-/- mice tend to have increased
bone mass and bone formation compared to wildtype ones [34]. This implies that ApoE
may have an impact on osteogenic genes.
Atheroma calcification is actively regulated by a combination of inflammatory
mediators, matrix components and apoptosis [4, 52, 95, 96]. Endothelial cells and
monocytes are involved in the early stages of VC, while VSMCs contribute to the later
stages of calcium deposition by proliferation and migration [79, 97]. Here our data
showed

aortic

rings

isolated

from

ApoE-/-

mice,

when

cultured

in

calcification-inducing medium, produced a greater extent of calcification than WT mice,
suggesting factors other than inflammation and cholesterol might affect the process of
calcification. Due to the complexity of the in vivo environment surrounding
atherosclerotic calcification areas and relevant cellular players, there is not much
known about whether the depletion of ApoE in one specific type of cell will alter the
pattern of calcification.
In this study, VSMCs were isolated from thoracic aortas of ApoE-/- and WT
mice, respectively. Cells were treated with Pi and induced to calcify. We observed that
ApoE-/- VSMCs generated significantly more calcium mineralization than WT cells
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when cultured in calcifying medium. By introducing ApoE back into ApoE-/- cells,
calcification was reduced dramatically. Therefore, our current study documents the first
direct evidence showing that ApoE deficiency worsens calcification in vitro. The loss
of smooth muscle lineage markers is required for the phenotypic transition from
VSMCs to osteoblasts and we found that smooth muscle markers SM22α and αSMA
both have weaker expression in ApoE-/- VSMCs. Osteopontin(OPN), on the other hand,
is a multifunctional protein and highly expressed in bones and calcified tissues[98].
OPN promotes ectopic calcification regression, serving as an inhibitor of mineral
deposition; depletion of OPN makes VSMCs more susceptible to Pi-induced
calcification in vitro [99]. We did find that restoration of ApoE successfully rescued the
decrease of SM22α, αSMA and OPN in ApoE-/- VSMCs. However, no obvious
difference of Runx2 expression levels was observed between WT, ApoE-/- and ApoE
overexpressing cells, which indicates that smooth muscle specific markers are affected
by molecular regulators other than Runx2. This is consistent with the finding that
Runx2 deficiency did not alter basal SMC markers in mice [100]. Type I collagen can
be produced by VSMCs and was found to be abundant in the medial layer of calcified
aortic tissues and atherosclerotic plaques. In vitro, type I collagen matrix promotes
calcification of vascular cells [101].
Apoptosis is another biological process strongly linked to vascular calcification,
but the underlying mechanisms are not fully understood yet [52]. Apoptosis usually
precedes VC and/or happens during the initiation of VC. It is established that apoptotic
bodies and necrotic debris of VSMCs promotes nucleation of calcium and thus
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enhances calcification [102]. Although it is known to protect endothelial cell against
apoptosis [103], whether ApoE suppresses VC via inhibition of apoptosis in VSMCs
remains unclear. However, there is evidence suggesting that ApoE-/- mice are more
sensitive to endoplasmic reticulum stress (ERS) [104], while ERS-related apoptosis is
known to promote vascular calcification in VSMCs [105]. Therefore, it is possible that
ApoE diminishes calcification by suppression of apoptosis, but the signaling pathways
involved need to be identified.
The heterogeneity of VSMCs isolated from aortas has been described before
[106]. A Shioi et al. cloned calcifying vascular cells (CVC) from bovine aortas and
these cells were able to form nodules that mineralized spontaneously in vitro [107]. The
cellular components of CVC are later identified to include VSMCs in the media, which
have many features of microvascular pericytes and differ from conventional VSMCs
[108]. In vivo studies indicated that there could be a pluripotent stem cell-like
population in the artery walls, which can undergo osteogenic differentiation [109].
Hence, it is possible that ApoE-/- mice aortas comprise a larger population of either
CVC or osteogenesis-capable stem cells that render these mice prone to VC.
ApoE is a secreted protein and under most circumstances affects cell physiology
by binding to receptors on cellular membranes. Identified ApoE receptors include
apolipoprotein E receptor 2(ApoER2), the low density lipoprotein receptor (LDLR) and
the very low density lipoprotein receptor (VLDLR), most of which have been found in
VSMCs [76]. Ligand-receptor interactions might be critical in protecting VSMCs
against calcification. Intracellular ApoE, on the other hand, acts as a regulator of
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cellular physiology as well. The accumulation of ApoE protein in endoplasmic
reticulum, for instance, is closely related to the processing of amyloid precursor
proteins in monkey kidney fibroblasts [110]. Even so, very few studies were done to
identify the relationship between expression level and function of intracellular ApoE
during calcification of VSMCs, due to the difficulty of stably expressing intracellular
ApoE for the long term. Therefore, it is possible that our observation on the effect of
ApoE deficiency on VC partially relies on the loss of intracellular ApoE. Further
studies will be needed to better differentiate the functionality between endogenous
ApoE and exogenous ApoE during calcification.
Summarizing the above discussion, when cultured under the condition in absence
of hypercholesterolemia and inflammation, ApoE-/- VSMCs inherently express high
levels of osteogenic genes. They become more susceptible to calcification induced by
osteogenic stimuli, such as inorganic phosphate, which may help explain why ApoE-/mice tend to develop vascular calcification more easily than WT mice.
Previous work by other groups have revealed different biological functions of
ApoE,

including

regulation

of

glucose

metabolism,

lipid

transport

and

neurogenesis[111]. However, the role of ApoE in vascular calcification and specific
pathways involved has not been addressed. The data from the current study present the
first experimental evidence that ApoE attenuates calcification of ApoE-/- VSMCs via
inhibition of the canonical Wnt/β-catenin pathway.
Vascular

calcification

represents

a

process

involving

the

irreversible

accumulation of calcium mineralization in arteries and the subsequently hardening of
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blood vessels. Hence, therapeutic strategies aimed at prevention of calcification are
urgently needed. Vascular calcification shares various features with osteogenesis, both
of which have ApoE as an important regulator. The best-known phenotype of ApoE-/mice is their susceptibility to develop atheroma, and calcification has been regarded as
a hallmark of atherosclerosis.
Calcium deposition is commonly found in advanced atherosclerotic plaques.
Senile ApoE-/- mice tend to have serious valvular calcification also, especially in mice
with chronic kidney failure [112]. ApoE appears to be regulated by BMP-2[33] and
expressed in the later stages of osteoblast differentiation [34]. Kim et al. found ApoE
inhibited osteoclast differentiation via c-Fos and NF-κB in bone marrow-derived
macrophages [113]. Besides, a high phosphate diet and nephrectomy resulted in
exacerbated vascular calcification in ApoE-deficient mice [114].
Therefore, ApoE-/- mice have been used as an ideal animal model to study
calcification. VSMCs, with their extensive plasticity, undergo phenotypic changes in
normal development, disease states, and in response to environmental cues [50]. As the
major structural component of vascular walls, VSMCs determine the stiffness of blood
vessels [115]. In our study, experiments were performed in cultured VSMCs isolated
from murine aortas, independent of the influence of inflammatory responses and
cholesterol. Here we found ApoE rescue the loss of smooth muscle lineage marker
SM22α and prevented the stimulated expressions of osteoblast markers including
Runx2, ALP, BMP-2, osteopontin and osteocalcin. Further, we observed ApoE
significantly reduced calcium deposition in VSMCs. This offers evidence for the
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importance of ApoE in inhibiting the phenotypic transition of VSMCs into
osteoblast-like cells, suggesting the possible function of ApoE in maintaining pliability
of aortas.
The Wnt/β-catenin pathway plays an indispensible part in vascular calcification.
In vitro studies showed that the Wnt/β-catenin pathway is activated when valvular
interstitial cells differentiate into ostoblast-like cells [41]. Wnt/β-catenin has been
reported to be activated in several osteoblast or osteoblast precursor cell lines,
including C3H10T1/2 cells and C2C12 cells [42], which implicate its importance in the
regulation of osteogenesis. Accumulation of the pathway proteins was observed in
valves, coronary arteries and aortas that undergo calcification [116, 117].
Martí
nez-Moreno et al. found that in VSMCs paricalcitol retarded phosphate-induced
calcification by preventing Wnt/β-catenin activation [118]. Beazley et al. noted that
transglutaminase 2-mediated β-catenin activation contributed to calcification of
VSMCs caused by combined treatment of warfarin and elevated concentration of
phosphate [119]. When β-catenin signalling is inactive, cytoplasmic β-catenin is subject
to constant degradation by Axin1 complex, which prevents it from translocating into
the nucleus [120]. Binding of Wnt ligands to frizzled and LRP5/6 receptor complex
recruits Axin1 to the receptor, thus enabling β-catenin to accumulate in the cytoplasm
and travel to the nucleus [37]. As a response to a calcification-inducing stimulus such
as high phosphorus levels, the β-catenin pathway becomes activated, and increased
nuclear β-catenin acts as a transcription factor that leads to enhanced expression of
downstream osteogenic genes, including osteopontin (OPN) and osteocalcin (OCN),
112

resulting in enhanced calcification[96]. Here we found ApoE suppressed the
translocalization of β-catenin into the nucleus as well as inhibited the activation of
β-catenin target genes including Axin2, CyclinD1 and Tcf4 in calcifying VSMCs.
Both LRP5 and LRP6 receptors are required for canonical Wnt/β-catenin
signalling to be generated. ApoE is a ligand for LRP5 and predicted to bind to LRP6 as
well. Although whether ApoE recognizes LRP5/6 as a heteromer coreceptor stays
unclear, the regulatory effects of ApoE on the Wnt pathway have been observed [85,
86]. Notably, here we examined the impact of ApoE on calcification in ApoE-/VSMCs, which is depleted of intracellular ApoE. Therefore, it is very likely that the
effect of ApoE we observed in our study is dependent on the interaction of ApoE and
receptor(s) in VSMCs.
Together, our results suggest that ApoE attenuates vascular calcification via
regulation of the canonical Wnt/β-catenin pathway, and supplement of extracellular
ApoE is sufficient to achieve substantial decrease of calcium deposition in VSMCs and
significant

inhibition

of

calcification

markers,

providing

new

potential

pharmacotherapeutic options for treating vascular calcification in the future.
To date, few studies have related GTAP with calcification. In our study, we
found that GTAP expression was low in aortic VSMCs derived from ApoE-/- mice,
which indicates ApoE might have a regulatory effect on GTAP. However, calcification
induced by phosphate was dramatically alleviated in wildtype VSMCs that overexpress
wildtype GTAP (GTAPWT) or mutant GTAP (GTAPC351A), but not in ApoE-/- VSMCs
with overpression of GTAPWT or GTAPC351A. This implies the possibility that the
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inhibition of calcification by GTAP might depend on the expression of ApoE in
VSMCs; however, more results need to be obtained in order to draw a solid conclusion.
In order to explore the mechanism by which GTAP alters calcification, relevant
experiments were performed in our studies on mice and VSMCs that are capable of
ApoE expression.
We observed that GTAP ovexpression decreased the expression of Runx2, an
important transcription factor necessary for osteogenesis. Moreover, enhanced
expression of GTAP increased the level of smooth muscle lineage markers SM22α and
αSMA. Considering GTAP as an E2 ubiquitin-conjugating enzyme involved in protein
degradation, we suspected that the low level of Runx2 caused by GTAP overexpression
could result from shortened half-life of Runx2. Our data indicates Runx2 has a
prolonged half-life when GTAP was knocked down. Besides, Runx2 displayed a shorter
half-life in cells with wild type GTAP overexpression, while mutant GTAP which lost
the ubiquitin-conjugating ability rendered Runx2 protein more stable. Hence, we might
conclude

that

the

degradation

of

Runx2

is

partially

dependent

on

the

ubiquitin-conjugating enzyme activity of GTAP, which has never been reported before.
Grzmil P et al. found that GTAP-deficient (GTAP-/-) female mice have embryo
implantation failure and other reproduction-associated problems [87], but no obvious
phenotype was detected in male GTAP-/- mice. Nevertheless, we observed that aortic
rings dissected from GTAP-/- male mice were more sensitive to elevated concentration
of inorganic phosphate (Pi) in the culture medium. Aortic rings that do not express
GTAP showed a significantly higher level of calcification than wild type ones when
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incubated with 3.6mM Pi. Therefore, although GTAP-/- male mice don’t have overt
phenotypes under regular conditions, stress such as osteogenic chemicals, including Pi,
might induce the calcification-prone phenotype in the absence of GTAP, suggesting
GTAP possibly plays a role in protection against vascular calcification. Moreover,
phenotypes of mice depend on strain. Therefore, the reason that no clear signs of
vascular calcification were found in GTAP-/- mice in vivo could be due to stronger
resistance of 129/sv mice to atherosclerosis.
In this study, we found that the mutant GTAP with active cysteine replaced by
an alanine alleviated calcification significantly compared to vector or wild type GTAP
in VSMCs incubated with Pi. In addition, the mutant GTAP construct decreased protein
expression of Runx2 moderately, though not as much as the wildtype GTAP, in VSMCs.
All these results, when taken together, suggest that other than the ubiquitin-binding
core (UBC) domain, the RWD domain (RING finger, WD repeats, and yeast
DEAD-like helicases containing proteins) or the NH2-terminal domain in GTAP may
contribute to the regulation of calcification process as well. Of note, Alontaga AY et al.
have studied the function of RWD domain and observed the capability of RWD domain
to interact with Ubc9, another E2 ubiquitin-conjugating enzyme involved in
SUMOylation, one of the modifications similar to ubiquitination [121]. Enzymatic
assays revealed that the RWD domain may alleviate the inhibitory effect of Ubc9 on the
catalysis of SUMO-activating enzyme. Besides, our previous findings imply that the
localization of GTAP in the nucleus of embryonic stem cells (ESCs) partly depend on
the NH2-terminal domain of GTAP. The NH2-terminal domain of GTAP is comprised of
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a unique sequence which consists of multiple proline and gutamine residues often
observed in small P-rich proteins, which may be involved in cell differentiation[122].
These domains are potentially important for protein transport, compartmentalization
and interaction with chaperone proteins. Hence we speculate the negative regulation of
calcification by GTAP probably depends on these domains as well as the UBC domain.
In conclusion, the data from the current study demonstrate: 1)Increased
vascular calcification in the atherosclerotic mouse models is ApoE-dependent; 2)
Vascular smooth muscle cells with ApoE knockout are sensitive to calcification
induced by inorganic phosphate (Pi); 3) Pi-inducible osteogenic genes play a role in the
transformation of the contractile vascular smooth muscle cells into synthetic,
bone-morphogenic cells; 4) Vascular cells from atherosclerotic aortas have altered
expression of the Wnt/β-catenin pathway; and 5) GTAP can alleviate Pi-induced
calcification in mouse aortas and VSMCs; 6) Potent expression of GTAP is correlated
with a high expression of smooth muscle lineage markers (SM22α and αSMA) and
suppression and shorter half-life of osteogenic master regulator Runx2;
may

directly

or

indirectly

regulate

calcification

via

and 7) GTAP

ubiquitylation

of

osteogenesis-related genes or interaction with other E2s.
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Figure 28. Proposed mechanism for regulation of calcification by ApoE in vascular
smooth muscle cells (VSMCs). ApoE suppressed nuclear translocalization of β-catenin,
leading to inhibition of β-catenin-dependent transcription of osteogenic genes and
eventually alleviated calcification. ApoE enhanced GTAP expression, which results in a
shortened half-life of Runx2, a master transcription factor involved in calcification,
inhibiting the osteogenic transformation of VSMCs.
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